[go: up one dir, main page]

WO1996004388A1 - Nouveaux composes - Google Patents

Nouveaux composes Download PDF

Info

Publication number
WO1996004388A1
WO1996004388A1 PCT/EP1995/003036 EP9503036W WO9604388A1 WO 1996004388 A1 WO1996004388 A1 WO 1996004388A1 EP 9503036 W EP9503036 W EP 9503036W WO 9604388 A1 WO9604388 A1 WO 9604388A1
Authority
WO
WIPO (PCT)
Prior art keywords
dna
compound according
igg4
compound
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1995/003036
Other languages
English (en)
Inventor
Michael Joseph Browne
Kay Elizabeth Murphy
Conrad Gerald Chapman
Helen Elizabeth Clinkenbeard
Peter Ronald Young
Allan Richard Shatzman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Ltd
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9415379A external-priority patent/GB9415379D0/en
Priority to MX9700764A priority Critical patent/MX9700764A/es
Priority to BR9508469A priority patent/BR9508469A/pt
Priority to JP8506192A priority patent/JPH10503371A/ja
Priority to AU33825/95A priority patent/AU3382595A/en
Priority to CZ97256A priority patent/CZ25697A3/cs
Application filed by SmithKline Beecham Ltd, SmithKline Beecham Corp filed Critical SmithKline Beecham Ltd
Priority to EP95930435A priority patent/EP0770135A1/fr
Priority to NZ292124A priority patent/NZ292124A/xx
Publication of WO1996004388A1 publication Critical patent/WO1996004388A1/fr
Priority to NO970374A priority patent/NO970374L/no
Anticipated expiration legal-status Critical
Priority to PL95318380A priority patent/PL182665B1/pl
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the present invention relates to antagonists of human interleukin 4 (IL4) and/or human interleukin 13 (IL13) for the treatment of conditions resulting from undesirable actions of IL4 and/or IL13 such as certain IgE mediated allergic diseases, T cell mediated autoimmune conditions and inappropriate immune responses to infectious agents.
  • IL4 human interleukin 4
  • IL13 human interleukin 13
  • Interleukins are secreted peptide mediators of the immune response. Each of the known interleukins has many effects on the development, activation, proliferation and differentiation of cells of the immune system.
  • IL4 has a physiological role in such functions, but can also contribute to the pathogenesis of disease.
  • IL4 is associated with the pathway of B lymphocyte development that leads to the generation of IgE antibodies that are the hallmark of allergic diseases such as extrinsic asthma, rhinitis, allergic conjunctivitis, atopic dermatitis and anaphylaxis.
  • D 4 can also act as a general growth and differentiation factor for T lymphocytes that may contribute to tissue damage in certain autoimmune conditions such as insulin dependent diabetes, multiple sclerosis and rheumatoid arthritis and in graft rejection. D 4 can also suppress the generation of cell-mediated responses required for the control of infectious disease. Antagonism of the effect of IL4 on T or B lymphocytes can therefore be expected to have beneficial effects on such diseases.
  • IL13 has been recently identified and shares similarity in many of the biological properties of IL4 (Minty, A. et al (1993), Nature 362, 248-250) including some aspect(s) of receptor structure/function (Aversa, G. et al (1993), J. Exp. Med. 178, 2213-2218).
  • Human IL4 consists of a single polypeptide chain of 129 amino acids with 2 possible N-glycosylation sites and 6 cysteines involved in 3 disulphide bridges (Le, H.V. et. al., (1988), J. Biol. Chem. 263, 10817-10823).
  • the amino acid sequence of IL4 and the positions of these disulphide bridges are known (Carr, C. et al, (1991) Biochemistry 30, 1515-1523).
  • the disulphide bridges are between residues 3 and 127, 24 and 65, and 46 and 99.
  • the molecular weight of IL4 varies with the extent of glycosylation from 15KDa (no glycosylation) to 60KDa or more (hyperglycosylated IL4).
  • the DNA sequence for human IL4 has also been described by Yokota, T. et. al., P.N.A.S. 1986 83 5894-5898.
  • WO 93/10235 describes certain mutants of IL4 which are EL4 antagonists or partial antagonists.
  • EP-A-0464 533 discloses fusion proteins comprising various portions of the constant region of immunoglobulin molecules together with another human protein or part thereof.
  • the present invention provides a soluble protein having IL4 and/or IL13 antagonist or partial antagonist activity, comprising an IL4 mutant or variant fused to least one human immunoglobulin constant domain or fragment thereof.
  • mutant or variant encompasses any molecule such as a truncated or other derivative of the IL4 protein which retains the ability to antagonise IL4 and/or IL13 following internal administration to a human.
  • Such other derivatives can be prepared by the addition, deletion, substitution, or rearrangement of amino acids or by chemical modifications thereof.
  • DNA polymers which encode mutants or variants of EL4 may be prepared by site-directed mutagenesis of the cDNA which codes for IL4 by conventional methods such as those described by G.
  • IL4 and/or IL13 antagonist or partial antagonist activity means that, in the assay described by Spits et al (J. Immunology 139, 1142 (1987)), LL4- stimulated T cell proliferation is inhibited in a dose-dependent manner.
  • Suitable IL4 mutants are disclosed in WO 93/10235, wherein at least one amino acid, naturally occuring in wild type IL4 at any one of positions 120 to 128 inclusive, is replaced by a different natural amino acid.
  • the tyrosine naturally occurring at position 124 may be replaced by a different natural amino acid, such as glycine or, more preferably, aspartic acid.
  • the immunoglobulin may be of any subclass (IgG, IgM, IgA, IgE), but is preferably IgG, such as IgGl, IgG3 or IgG4.
  • the said constant domain(s) or fragment thereof may be derived from the heavy or light chain or both.
  • the invention encompasses mutations in the immunoglobulin component which eliminate undesirable properties of the native immunoglobulin, such as Fc receptor binding and or introduce desirable properties such as stability. For example, Angal S., King D.J., Bodmer M.W., Turner A., Lawson A.D.G., Roberts G., Pedley B.
  • the constant domain(s) or fragment thereof is preferably the whole or a substantial part of the constant region of the heavy chain of human IgG, most preferably IgG4.
  • the IgG component consists of the CH2 and CH3 domains and the hinge region of IgGl including cysteine residues contributing to inter-heavy chain disulphide bonding, for example residues 11 and 14 of the IgGl hinge region (Frangione B. and Milstein C, Nature vol216pp939-941, 1967).
  • the IgGl component consists of amino acids corresponding to residues 1-4 and 6-15 of the hinge, 1-110 of CH2 and 1-107 of CH3 of IgGl described by Ellison J., Berson B. and Hood L.
  • the hinge is changed from cysteine in the published IgGl sequence to alanine by alteration of TGT to GCC in the nucleotide sequence.
  • the IgG component is derived from IgG4, comprising the CH2 and CH3 domains and the hinge region including cysteine residues contributing to inter-heavy chain disulphide bonding, for example residues 8 and 11 of the IgG4 hinge region (Pinck J.R. and Milstein C, Nature vol216pp941-942, 1967).
  • the IgG4 component consists of amino acids corresponding to residues 1-12 of the hinge, 1-110 of CH2 and 1-107 of CH3 of IgG4 described by Ellison J., Buxbaum J. and Hood L., DNA vollppl 1-18, 1981.
  • residue 10 of the hinge (residue 241, Kabat numbering) is altered from serine (S) in the wild type to proline (P) and residue 5 of CH2 (residue 248, Kabat numbering) is altered from leucine (L) in the wild type to glutamate (E).
  • Fusion of the IL4 mutant or variant to the Ig constant domain or fragment is by C-terminus of one component to N-terminus of the other.
  • the IL4 mutant or variant is fused via its C-terminus to the N-terminus of the Ig constant domain or fragment.
  • the amino acid sequence of the fusion protein of the invention is represented by SEQ ID No:4, SEQ ID No:7 or SEQ ID No: 10.
  • the invention provides a process for preparing a compound according to the invention which process comprises expressing DNA encoding said compound in a recombinant host cell and recovering the product.
  • the DNA polymer comprising a nucleotide sequence that encodes the compound also forms part of the invention.
  • the DNA polymer comprises or consists of the sequence of SEQ ID No:3, SEQ ID No:6 or SEQ ID No:9.
  • the process of the invention may be performed by conventional recombinant techniques such as described in Maniatis et. al., Molecular Cloning - A Laboratory Manual; Cold Spring Harbor, 1982 and DNA Cloning vols I, II and III (D.M. Glover ed., IRL Press Ltd).
  • the process may comprise the steps of: i) preparing a replicable expression vector capable, in a host cell, of expressing a DNA polymer comprising a nucleotide sequence that encodes said compound; ii) transforming a host cell with said vector; iii) culturing said transformed host cell under conditions permitting expression of said DNA polymer to produce said compound; and iv) recovering said compound.
  • the invention also provides a process for preparing the DNA polymer by the condensation of appropriate mono-, di- or oligomeric nucleotide units.
  • the preparation may be carried out chemically, enzymatically, or by a combination of the two methods, in vitro or in vivo as appropriate.
  • the DNA polymer may be prepared by the enzymatic ligation of appropriate DNA fragments, by conventional methods such as those described by D. M. Roberts et al in Biochemistry 1985, 24, 5090-5098.
  • the DNA fragments may be obtained by digestion of DNA containing the required sequences of nucleotides with appropriate restriction enzymes, by chemical synthesis, by enzymatic polymerisation on DNA or RNA templates, or by a combination of these methods.
  • Digestion with restriction enzymes may be performed in an appropriate buffer at a temperature of 20°-70°C, generally in a volume of 50 ⁇ l or less with 0.1-10 ⁇ g DNA.
  • Enzymatic polymerisation of DNA may be carried out in vitro using a DNA polymerase such as DNA polymerase I (Klenow fragment) in an appropriate buffer containing the nucleoside triphosphates dATP, dCTP, dGTP and dTTP as required at a temperature of 10°-37°C, generally in a volume of 50 ⁇ l or less.
  • Enzymatic ligation of DNA fragments may be carried out using a DNA ligase such as T4 DNA ligase in an appropriate buffer at a temperature of 4°C to ambient, generally in a volume of 50 ⁇ l or less.
  • the chemical synthesis of the DNA polymer or fragments may be carried out by conventional phosphotriester, phosphite or phosphoramidite chemistry, using solid phase techniques such as those described in 'Chemical and Enzymatic Synthesis of Gene Fragments - A Laboratory Manual' (ed. H.G. Gassen and A. Lang), Verlag Chemie, Weinheim (1982),or in other scientific publications, for example M.J. Gait, H.W.D. Matthes, M. Singh, B.S. Sproat, and R.C. Titmas, Nucleic Acids Research, 1982, 10, 6243; B.S. Sproat and W. Bannwarth, Tetrahedron Letters, 1983, 24, 5771; M.D. Matteucci and M.H Caruthers, Tetrahedron Letters, 1980, 21, 719; M.D.
  • the DNA polymer is preferably prepared by ligating two or more DNA molecules which together comprise a DNA sequence encoding the compound.
  • a particular process in accordance with the invention comprises ligating a first DNA molecule encoding a said IL4 mutant or variant and a second DNA molecule encoding a said immunoglobulin domain or fragment thereof.
  • the DNA molecules may be obtained by the digestion with suitable restriction enzymes of vectors carrying the required coding sequences or by use of polymerase chain reaction technology.
  • the precise structure of the DNA molecules and the way in which they are obtained depends upon the structure of the desired product.
  • the design of a suitable strategy for the construction of the DNA molecule coding for the compound is a routine matter for the skilled worker in the art.
  • the expression of the DNA polymer encoding the compound in a recombinant host cell may be carried out by means of a replicable expression vector capable, in the host cell, of expressing the DNA polymer.
  • the expression vector is novel and also forms part of the invention.
  • the replicable expression vector may be prepared in accordance with the invention, by cleaving a vector compatible with the host cell to provide a linear DNA segment having an intact replicon, and combining said linear segment with one or more DNA molecules which, together with said linear segment, encode the compound, under ligating conditions.
  • the ligation of the linear segment and more than one DNA molecule may be carried out simultaneously or sequentially as desired.
  • the DNA polymer may be preformed or formed during the construction of the vector, as desired.
  • the choice of vector will be determined in part by the host cell, which may be prokaryotic, such as E. coli, or eukaryotic, such as mouse C127, mouse myeloma, Chinese hamster ovary or Hela cells, fungi e.g. filamentous fungi or unicellular yeast or an insect cell such as Drosophila.
  • the host cell may also be a transgenic animal.
  • Suitable vectors include plasmids, bacteriophages, cosmids and recombinant viruses derived from, for example, baculoviruses, vaccinia or Semliki Forest virus.
  • the preparation of the replicable expression vector may be carried out conventionally with appropriate enzymes for restriction, polymerisation and ligation of the DNA, by procedures described in, for example, Maniatis ej al., cited above. Polymerisation and ligation may be performed as described above for the preparation of the DNA polymer. Digestion with restriction enzymes may be performed in an appropriate buffer at a temperature of 20°-70°C, generally in a volume of 50 ⁇ l or less with 0.1- lO ⁇ g DNA.
  • the recombinant host cell is prepared, in accordance with the invention, by transforming a host cell with a replicable expression vector of the invention under transforming conditions.
  • Suitable transforming conditions are conventional and are described in, for example, Maniatis et al., cited above, or "DNA Cloning" Vol. ⁇ , D.M. Glover ed., IRL Press Ltd, 1985.
  • a bacterial host such as E. coli may be treated with a solution of CaCl2 (Cohen et al, Proc. Nat. Acad. Sci., 1973, 69, 2110) or with a solution comprising a mixture of RbCl, MnCl2, potassium acetate and glycerol, and then with 3-[N-morpholino]- propane-sulphonic acid, RbCl and glycerol.
  • Mammalian cells in culture may be transformed by calcium co-precipitation of the vector DNA onto the cells.
  • the invention also extends to a host cell transformed with a replicable expression vector of the invention.
  • Culturing the transformed host cell under conditions permitting expression of the DNA polymer is carried out conventionally, as described in, for example, Maniatis et al and "DNA Cloning" cited above.
  • the cell is supplied with nutrient and cultured at a temperature below 45°C.
  • the expression product is recovered by conventional methods according to the host cell.
  • the host cell is bacterial, such as E. coli it may be lysed physically, chemically or enzymatically and the protein product isolated from the resulting lysate. If the product is to be secreted from the bacterial cell it may be recovered from the periplasmic space or the nutrient medium. Where the host cell is mammalian, the product may generally be isolated from the nutrient medium.
  • the DNA polymer may be assembled into vectors designed for isolation of stable transformed mammalian cell lines expressing the product; e.g. bovine papillomavirus vectors or amplified vectors in Chinese hamster ovary cells (DNA cloning Vol.II D.M. Glover ed. IRL Press 1985; Kaufman, R.J. £1 aL, Molecular and Cellular Biology 5, 1750-1759, 1985; Pavlakis G.N. and Hamer, D.H., Proceedings of the National Academy of Sciences (USA) 80, 397-401, 1983; Goeddel, D.V. et al., European Patent Application No. 0093619, 1983).
  • bovine papillomavirus vectors or amplified vectors in Chinese hamster ovary cells
  • Compounds of the present invention have IL4 and/or IL13 antagonist activity and are therefore of potential use in the treatment of conditions resulting from undesirable actions of IL4 and or IL13 such as IgE mediated allergic diseases and T cell mediated autoimmune conditions or chronic microbial infection.
  • the invention therefore further provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of the invention and a pharmaceutically acceptable carrier.
  • the compound will normally be employed in the form of a pharmaceutical composition in association with a human pharmaceutical carrier, diluent and/or excipient, although the exact form of the composition will depend on the mode of administration.
  • the compound may, for example, be employed in the form of aerosol or nebulisable solution for inhalation or sterile solutions for parenteral administration.
  • the dosage ranges for administration of the compounds of the present invention are those to produce the desired effect on the IL4 and/or IL13 mediated condition, for example whereby IgE antibody mediated symptoms are reduced or progression of the autoimmune disease is halted or reversed.
  • the dosage will generally vary with age, extent or severity of the medical condition and contraindications, if any.
  • the unit dosage can vary from less than lmg to 300mg, but typically will be in the region of 1 to 20mg per dose, in one or more doses, such as one to six doses per day, such that the daily dosage is in the range 0.02-40mg/kg.
  • compositions suitable for injection may be in the form of solutions, suspensions or emulsions, or dry powders which are dissolved or suspended in a suitable vehicle prior to use.
  • Fluid unit dosage forms are prepared utilising the compound and a pyrogen-free sterile vehicle.
  • the compound depending on the vehicle and concentration used, can be either dissolved or suspended in the vehicle. Solutions may be used for all forms of parenteral administration, and are particularly used for intravenous infection. In preparing solutions the compound can be dissolved in the vehicle, the solution being made isotonic if necessary by addition of sodium chloride and sterilised by filtration through a sterile filter using aseptic techniques before filling into suitable sterile vials or ampoules and sealing. Alternatively, if solution stability is adequate, the solution in its sealed containers may be sterilised by autoclaving. Advantageously additives such as buffering, solubilising, stabilising, preservative or bactericidal, suspending or emulsifying agents and or local anaesthetic agents may be dissolved in the vehicle.
  • Dry powders which are dissolved or suspended in a suitable vehicle prior to use may be prepared by filling pre-sterilised drug substance and other ingredients into a sterile container using aseptic technique in a sterile area.
  • the drug and other ingredients may be dissolved in an aqueous vehicle, the solution is sterilised by filtration and distributed into suitable containers using aseptic technique in a sterile area. The product is then freeze dried and the containers are sealed aseptically.
  • Parenteral suspensions, suitable for intramuscular, subcutaneous or intradermal injection are prepared in substantially the same manner, except that the sterile compound is suspended in the sterile vehicle, instead of being dissolved and sterilisation cannot be accomplished by filtration.
  • the compound may be isolated in a sterile state or alternatively it may be sterilised after isolation, e.g. by gamma irradiation.
  • a suspending agent for example polyvinylpyrrolidone is included in the composition to facilitate uniform distribution of the compound.
  • Compositions suitable for administration via the respiratory tract include aerosols, nebulisable solutions or microfine powders for insufflation. In the latter case, particle size of less than 50 microns, especially less than 10 microns, is preferred. Such compositions may be made up in a conventional manner and employed in conjunction with conventional administration devices.
  • a method of treating conditions resulting from undesirable actions of IL4 and/or IL13 which comprises administering to the sufferer an effective amount of a compound of the invention.
  • the invention further provides a compound of the invention for use as an active therapeutic substance, in particular for use in treating conditions resulting from undesirable actions of EL4 and/or EL 13.
  • the invention also provides the use of a compound of the invention in the manufacture of a medicament for treating conditions resulting from undesirable actions of IL4 and or IL13.
  • the IL4.Y124D cDNA was inserted into the expression vector pTR312, using the Hindlll and Bglll sites, (M J Browne, J E Carey, C G Chapman, A W R Tyrrell, C Entwisle, G M P Lawrence, B Reavy, I Dodd, A Esmail & J H
  • PCR primers were designed to include restriction enzyme sites, flanked by 10-15 nucleotide base pairs to "anchor" the primers at each end.
  • the primer sequences were as follows:
  • the 570bp fragment represents the full-length IL4.Y124D variant of IL4 and was present because the digest was incomplete. The two smaller fragments were produced due to the presence of an EcoRI site within the IL4.Y124D cDNA.
  • the 570bp band was purified by the Geneclean TM procedure, and ligated into Bluescript KS + TM which was prepared by digestion with EcoRI and Kpnl followed by Geneclean TM . A Bluescript KS+/IL4.Y124D recombinant was thus generated. Large amounts of this recombinant DNA were produced using the Promega "Magic Maxiprep" method.
  • the IL4.Y124D insert was excised from the Bluescript recombinant using Smal and Kpnl.
  • the COSFcLink vector (Table 1) contains human IgGl cDNA encoding amino acids 1-4 and 6-15 of the hinge, 1-110 of CH2 and 1-108 of CH3 described by Ellison J., Berson B. and Hood L. E., Nucleic Acids Research vollO, pp4071-4079, 1982. Residue 5 of the hinge is changed from cysteine in the published IgGl sequence to alanine by alteration of TGT to GCC in the nucleotide sequence. This was cloned from the human IgG plasma cell leukemia ARH-77 (American Type Tissue Collection), using RT-PCR and fully sequenced to confirm identity with the published sequence [patent application publication WO 92/00985]
  • COSFc The construction of COSFc began with a pUCl ⁇ vector containing the human IgGl cDNA above (pUC18-Fc), which was digested with Kpnl and SacII, deleting the CHI, hinge and part of CH2. The deleted region was replaced with a PCR amplified fragment containing the hinge-CH2 region as follows. Using the following PCR primers:
  • a DNA fragment containing the hinge-CH2 region was amplified from pUC18-Fc, digested with Kpnl and SacII, gel purified and cloned into the Kpnl/SacII digested pUC18-Fc vector.
  • the Cys which occurs at position 230 (Kabat numbering; Kabat et al., "Sequences of Proteins of Immunological Interest, 5th Edition, US Department of Health and Human Services, NIH Publication No. 91-3242 (1991)) of the IgG 1 heavy chain, was altered to an Ala through a TGT to GCC substitution in the nucleotide sequence.
  • the entire hinge-CH2-CH3 insert in pUC18-Fcmod was removed in a single DNA fragment with Kpnl and Xbal, gel purified, and ligated into SFcRlCos4 cut with Kpnl and Xbal to create COSFc.
  • SFcRlCos4 is a derivative of pST4DHFR (Deen, K , McDougal, JS, Inacker, R, Folena-Wasserman, G, Arthos, J, Rosenberg, J, Maddon, PJ, Axel, R, and Sweet, RW. Nature 3_3 .
  • sFcRl soluble Fc receptor type I
  • BGH bovine growth hormone
  • DHFR dihydrofolate reductase
  • the COSFcLink vector was made from COSFc by inserting an oligonucleotide linker at the unique EcoRI site of the vector, which recreates this EcoRI site, and also introduces BstEII. Pstl and EcoRV cloning sites.
  • the oligonucleotides used were:
  • the COSFcLink vector was prepared by digesting with EcoRV and Kpnl as follows: 5 ⁇ g DNA was incubated with 15 units EcoRV in react 2 at 37°C for 5 hours, followed by ethanol precipitation. The resulting DNA was digested with Kpnl in react 4 at 37°C for 3 hours, and ethanol precipitated. The IL4.Y124D/SmaI/KpnI and the COSFcLink/EcoRV/Kpnl fragments were ligated together to form plasmid pDB951, which encodes the IL4.Y124D/IgGl fusion protein.
  • the ligation was achieved using an Amersham DNA ligation kit, product code RPN 1507, the reactions being incubated at 16°C overnight.
  • the ligation reaction products were transformed into Promega JM109 competent cells (high efficiency) and plated onto Luria Broth agar containing ampicillin at 50 ⁇ g/ml. Transformants were cultured in Luria Broth (containing ampicillin at 50 ⁇ g/ml) and DNA prepared using Promega "Magic Minipreps”. Production of an IL4.Y124D/COSFcLink recombinant DNA was verified by restriction digests and DNA sequencing. The complete IL4.Y124D sequence and the junctions with the COSFcLink DNA were confirmed by DNA sequencing (Table 2).
  • the coding sequence of the recombinant IL4.Y124D/IgGl DNA is shown in Table 3 and the amino acid sequence of the fusion protein is shown in Table 4.
  • the IL4.Y124D/COSFcLink recombinant DNA was prepared and purified using caesium chloride gradients and the DNA used to transiently transfect HeLa cells.
  • HeLa cells were grown in MEM ⁇ medium (Gibco) with 10% foetal calf serum and 1% glutamine.
  • MEM ⁇ medium Gibco
  • 1 x 10 ⁇ HeLa cells were seeded in 15mls RPMI-1640 medium with 10% newborn calf serum, 1% glutamine ("seeding medium"), in a 75cm ⁇ flask, four days prior to transfection. On the day prior to transfection, a further 12.5mls seeding medium was added to each flask. On the day of transfection, the medium was changed to 15mls of "transfection medium” (MEM medium with Earle's salts containing 10% newborn calf serum and 1% non essential amino acids), at time zero.
  • transfection medium MEM medium with Earle's salts containing 10% newborn calf serum and 1% non essential amino acids
  • the IL4.Y124D/IgGl chimera inhibited ⁇ H thymidine incorporation by human peripheral blood T lymphocytes stimulated with 133pM IL4 in a dose dependent manner.
  • PCR was performed to amplify the IL4.Y124D coding region and introduce a silent nucleotide substitution at the 3' end which creates a Xhol site.
  • substrate for the PCR reaction 20ng of linearised pDB951 plasmid (Example 1.1(c)) was used.
  • the oligonucleotide primers used were as follows:
  • a second PCR reaction was performed to amplify the hinge-CH2-CH3 fragment of the human IgG4 heavy chain.
  • the substrate for this was a synthetic human IgG4 heavy chain cDNA, the sequence of which is described in Table 5, and is based on the Genbank sequence GB:HUMIGCD2 (Ellison J., Buxbaum J. and Hood L.E., DNA ill 1-18, 1981). Numerous silent substitutions were made to the published nucleotide sequence.
  • the gene was assembled by combining two 0.5Kb synthetic DNA fragments. Each 0.5Kb fragment was made by annealing a series of overlapping oligonucleotides and then filling in the gaps by PCR.
  • the two 0.5Kb fragments were joined at the SacII site and inserted into the pCR2 vector.
  • a 1.0Kb Apal-Bglll fragment containing the entire constant region was isolated and ligated into an expression vector, pCD, containing a humanized IL4 specific variable region. This construct was used as the PCR substrate to amplify the hinge-CH2-CH3 region of IgG4.
  • the oligonucleotide primers used for amplification of the IgG4 hinge- CH2-CH3 region were as follows:
  • PCR products of approximately 700b ⁇ (hinge-CH2-CH3 of IgG4) and 400bp (IL4.Y124D) were obtained and purified using the Promega "Magic PCR cleanup" kit.
  • the purified PCR reactions were then digested with the following enzymes to create "sticky ends": Xhol and Xbal for IgG4 and EcoRV and Xhol for H .Y124D.
  • the digests were incubated at 37°C for 3 hours and then ethanol precipitated.
  • the resulting DNAs were analysed by gel electrophoresis and gave sizes of approximately 690bp (hinge-CH2-CH3 of IgG4) and 370bp (IL4.Y124D).
  • a vector was prepared into which to ligate the hinge-CH2-CH3 of IgG4 and IL4.Y124D PCR fragments by digesting pDB951 (IL4.Y124D in COSFcLink) with EcoRV and Xbal to remove most of the IL4.Y124D/IgGl fusion molecule. The only part remaining is approximately 75bp at the 5' end of IL4, which is not present in the IL4.Y124D EcoRV/XhoI fragment produced by PCR amplification. 5 ⁇ g of pDB951 DNA was digested in a total volume of 30 ⁇ l using react 2 buffer (GibcoBRL). The resulting 5.8Kb DNA fragment was purified using the Geneclean procedure.
  • the three fragments described (IL4.Y124D EcoRV/XhoI, hinge-CH2- CH3 of IgG4 Xhol/Xbal and the 5.8Kb fragment resulting from EcoRV/Xbal digestion of pDB951) were ligated together to form plasmid pDB952, which encodes the IL4.Y124D/IgG4 fusion protein.
  • the ligation was carried out using a DNA ligation kit from Amersham (product code RPN 1507), incubating the reactions at 16° C overnight.
  • the ligation reaction products were transformed into Promega JM109 competent cells (high efficiency) and plated onto Luria Broth agar containing ampicillin at 50 ⁇ g/ml.
  • Transformants were cultured in Luria Broth (containing ampicillin at 50 ⁇ g/ml) and DNA prepared using Promega "Magic Minipreps”. Production of an IL4.Y124D ⁇ gG4 recombinant DNA was verified by restriction digests, and the complete IL4.Y124D and hinge-CH2-CH3 IgG4 regions were verified by DNA sequencing. Table 6 describes the sequence of the coding region only of the FL4.Y124D/IgG4 fusion molecule, and Table 7 contains the amino acid sequence of the fusion protein. The IL4.Y124D/IgG4 recombinant DNA was prepared and purified using caesium chloride gradients and the DNA used to transiently transfect HeLa cells.
  • HeLa cells were grown in MEM ⁇ medium (Gibco) with 10% foetal calf serum and 1% glutamine.
  • MEM ⁇ medium Gibco
  • 1 x 10" HeLa cells were seeded in 15mls RPMI-1640 medium with 10% newborn calf serum, 1% glutamine ("seeding medium"), in a 75cm ⁇ flask, four days prior to transfection. On the day prior to transfection, a further 12.5mls seeding medium was added to each flask. On the day of transfection, the medium was changed to 15mls of "transfection medium” (MEM medium with Earle's salts containing 10% newborn calf serum and 1% non essential amino acids), at time zero.
  • transfection medium MEM medium with Earle's salts containing 10% newborn calf serum and 1% non essential amino acids
  • the IL4.Y124D/IgG4 chimera inhibited ⁇ H thymidine incorporation by human peripheral blood T lymphocytes stimulated with 133pM IL4 in a dose dependent manner.
  • PCR is performed to amplify the IL4.Y124D coding region and introduce a silent nucleotide substitution at the 3' end which creates a Xhol site as described in Example 2.
  • a second PCR reaction is performed to amplify the hinge-CH2-CH3 fragment of the human IgG4 heavy chain PE variant.
  • residue 10 of the hinge is altered from serine (S) in the wild type to proline (P) and residue 5 of CH2 (residue 248, Kabat numbering) is altered from leucine (L) in the wild type to glutamate (E).
  • Angal S. King D.J., Bodmer M.W., Turner A., Lawson A.D.G., Roberts G., Pedley B. and Adair R., Molecular
  • the IgG4 PE variant was created using PCR mutagenesis on the synthetic human IgG4 heavy chain cDNA described in Table 5, and was then ligated into the pCD expression vector. It was this plasmid which was used as the substrate for the PCR reaction amplifying the hinge-CH2-CH3 fragment of IgG4 PE.
  • the sequence of the IgG4 PE variant is described in Table 8.
  • residues of the IgG4 nucleotide sequence which were altered to make the PE variant are as follows: referring to Table 8: residue 322 has been altered to "C” in the PE variant from “T” in the wild type; residue 333 has been altered to "G” in the PE variant from "A” in the wild type; and residues 343-344 have been altered to "GA” in the PE variant from "CT” in the wild type.
  • Oligonucleotide primers are used for amplification of the IgG4 PE variant hinge-CH2-CH3 region as described for the derivation of pDB952.
  • PCR products of approximately 700b ⁇ (hinge-CH2-CH3 of IgG4 PE mutant) and 400bp (IL4.Y124D) are obtained and purified using the Promega "Magic PCR cleanup" kit.
  • the purified PCR reactions are then digested with the following enzymes to create "sticky ends": Xhol and Xbal for IgG4 PE and EcoRV and Xhol for IL4.Y124D.
  • the digests are incubated at 37°C for 3 hours and then ethanol precipitated.
  • the resulting DNAs are of sizes of approximately 690bp (hinge-CH2- CH3 of IgG4 PE) and 370bp (IL4.Y124D).
  • the purified and digested PCR products are ligated into Bluescript KS + TM which is prepared by digestion with either Xhol and Xbal for the hinge-CH2-CH3 of IgG4 PE fragment or EcoRV and Xhol for the IL4.Y124D fragment, followed by GenecleanTM.
  • Bluescript KS + /hinge-CH2- CH3 of IgG4 PE recombinant and a Bluescript KS + /TL4.Y124D recombinant are thus generated. Large amounts of these DNAs are produced using the Promega "Magic Maxiprep" method.
  • the IgG4 PE hinge-CH2-CH3 fragment is excised from the Bluescript recombinant using Xhol and Xbal. The resulting fragment of approximately 690bp is purified by GenecleanTM to generate large amounts of the IgG4 PE hinge-CH2-CH3 Xhol/Xbal fragment.
  • the IL4.Y124D fragment is excised from the Bluescript recombinant using EcoRV and Xhol and the resulting fragment of approximately 370bp is purified by GenecleanTM.
  • a vector is prepared into which to ligate the hinge-CH2-CH3 of IgG4 PE and HAY124D fragments by digesting pDB951 with EcoRV and Xbal as described for the derivation of pDB952.
  • EcoRV/Xbal digestion of pDB951 are ligated together to form plasmid pDB953 using a DNA ligation kit from Amersham (product code RPN 1507), incubating the reactions at 16°C overnight.
  • the ligation reaction products are transformed into Promega JM109 competent cells (high efficiency) and plated onto Luria Broth agar containing ampicillin at 50 ⁇ g/ml. Transformants are cultured in Luria Broth (containing ampicillin at 50 ⁇ g/ml) and DNA prepared using Promega "Magic Minipreps".
  • IL4.Y124D/IgG4 PE variant recombinant DNA is verified by restriction digests, and the complete IL4.Y124D and hinge-CH2-CH3 IgG4 PE variant regions are verified by DNA sequencing.
  • Table 9 describes the sequence of the coding region only of the IL4.Y124D/IgG4 PE fusion molecule, and Table 10 contains the amino acid sequence of the fusion protein.
  • the IL4.Y124D/IgG4 PE recombinant DNA is prepared and purified using caesium chloride gradients and the DNA used to transiently transfect HeLa cells. 2. Expression of the fusion protein HeLa cells were grown in MEM ⁇ medium (Gibco) with 10% foetal calf serum and 1% glutamine.
  • the cells were subjected to a glycerol shock (15%v/v) and then left to incubate overnight in 12.5mls seeding medium containing 5mM sodium butyrate. The next day the cells were washed with PBS (Dulbecco's phosphate buffered saline) and 12.5mls "harvest medium” (RPMI-1640 with 2% of a 7.5% stock sodium bicarbonate solution) was added. After a further 24 hour incubation, the supernatants were removed, centrifuged at lOOOrpm for 5 minutes to remove cell debris and stored at either 4°C or -20°C.
  • PBS Dulbecco's phosphate buffered saline
  • 12.5mls "harvest medium” RPMI-1640 with 2% of a 7.5% stock sodium bicarbonate solution
  • the IL4.Y124D/IgG4 PE chimera inhibited ⁇ H thymidine incorporation by human peripheral blood T lymphocytes stimulated with 133pM IL4 in a dose dependent manner.
  • Example 4 Mammalian Expression vector containing DNA coding for IL4.Y124D/IgG4 PE.
  • the pCDN vector (Aiyar, N.. Baker, E., Wu, H-L., Nambi, P., Edwards, R. Trill, J.J., Ellis, C, Bergsma, D. Molecular and Cellular Biochemistry 131:75-86, 1994 contains the CMV promoter, a polylinker cloning region, and the BGH polyadenylation region.
  • This vector also contains a bacterial neomycin phosphotransferase gene (NEO) inserted between the ⁇ -globin promoter and SV40 polyadenylation region for GeneticinTM selection, the DHFR selection cassette inserted between the ⁇ -globin promoter and BGH polydenylation region for methotrexate (MTX) amplification, an ampicillin resistance gene for growth in bacteria, and a SV40 origin of replication.
  • NEO bacterial neomycin phosphotransferase gene
  • the pCDN vector was prepared by digesting with Ndel and BstXl as follows: 15 ⁇ g of DNA was incubated with 30 units of BstXl in react 2 (Gibco-BRL) at 55°C for 1 hour, and ethanol precipitated. The resulting DNA was digested with Ndel in react 2 at 37°C for 1 hour, and ethanol precipitated.
  • the IL4.Y124D/IgG4 PE fragment was prepared from pDB953 (Example 3.1) by digesting with BstXl and Ndel as follows: 15 ⁇ g of DNA was incubated with 30 units of BstXl in react 2 at 55°C for 1 hour, and ethanol precipitated. The resulting DNA was digested with Ndel in react 2 at 37°C for 1 hour, and ethanol precipitated.
  • the IL4.Y124D/IgG4 PE Ndel/BstXl and pCDN Ndel/BstXl fragments were ligated together to form the plasmid pCDN-IL4.Y124D/IgG4 PE.
  • the ligation was achieved using 2 units of T4 DNA Ligase (Gibco BRL) with T4 DNA Ligase buffer. The reactions were incubated at 16°C overnight.
  • the ligation reaction products were transformed into Gibco-BRL DH5a competent cells (subcloning efficiency) and plated onto Luria Broth agar containing 75 ug/ml ampicillin. Transformants were cultured in Luria Broth (containing ampicillin at 50 ug/ml) and DNA prepared by alkaline lysis. Production of a pCDN-
  • IL4.Y124D/IgG4 PE DNA was confirmed by restriction digests. The complete sequence of the recombinant LL4.Y124D/IgG4 PE DNA was confirmed by sequencing. The pCDN- EL4.Y124D/IgG4 PE recombinant DNA was prepared and purified using Qiagen columns and the DNA was used to transiently infect COS cells and electroporated into CHO cells to create stable clones.
  • CHO cells ACC-098 (a suspension cell line derived from CHO DG-44, Urlaub, G., Kas, E., Carothers, A.M. and Chasin, L.A. Cell, 33. 405-412, 1983) were grown in serum free growth medium WO 92/05246.
  • 15 ⁇ g of the pCDN-IL4.Y124D/IgG4 PE plasmid was digested using 30 units of Notl at 37°C for 3 hours to linearize the plasmid, and precipitated with ethanol.
  • the resulting DNA was resuspended in 50ul of 1 X TE (lOmM Tris, pH 8.0, ImM EDTA).
  • the DNA was electroporated into 1 X 10 7 ACC-098 cells, using a Bio Rad Gene Pulser set at 380V and 25 ⁇ Fd.
  • the cells were resupended into growth medium at 2.5 X 10 ⁇ cells/ml, and 200 ⁇ l of the cell suspension was plated into each well of a 96 well plate. 48 hours later the medium was switched to growth medium containing 400 ⁇ g/ml G418 (Geneticin). Twenty one days post selection, conditioned medium from the colonies which arose were screened by Elisa assay. The highest expressing colonies were transferred to 24 well plates in order to be scaled up.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Protéine soluble ayant une activité antagoniste complète ou partielle de IL4 (interleukine 4) et/ou de IL13, qui comprend un variant ou mutant de IL4 fusionné avec au moins un domaine constant d'immunoglobuline humaine ou fragment dudit domaine.
PCT/EP1995/003036 1994-07-29 1995-07-28 Nouveaux composes Ceased WO1996004388A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
NZ292124A NZ292124A (en) 1994-07-29 1995-07-28 Il-4 antagonist comprising a fusion of a mutant il-4-antibody fragment
BR9508469A BR9508469A (pt) 1994-07-29 1995-07-28 Proteína solúvel tendo antagonista il4 e/ou il13 ou atividade antagonista parcial composto processo para a preparação do mesmo polímero de DNA vetor de exemplo replicável célula hospedeira composição farmacêutica processo para tratar condições e uso do composto
JP8506192A JPH10503371A (ja) 1994-07-29 1995-07-28 新規化合物
AU33825/95A AU3382595A (en) 1994-07-29 1995-07-28 Novel compounds
CZ97256A CZ25697A3 (en) 1994-07-29 1995-07-28 Novel compounds
MX9700764A MX9700764A (es) 1994-07-29 1995-07-28 Compuestos novedosos.
EP95930435A EP0770135A1 (fr) 1994-07-29 1995-07-28 Nouveaux composes
NO970374A NO970374L (no) 1994-07-29 1997-01-28 Nye forbindelser
PL95318380A PL182665B1 (pl) 1994-07-29 1997-03-27 Rozpuszczalne białko mające aktywność antagonistyczną lub częściową aktywność antagonistyczną wobec IL4 i/lub IL13, sposób wytwarzania rozpuszczalnego białka, polimer DNA, replikujący wektor ekspresji, komórka gospodarza i środek farmaceutyczny

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9415379A GB9415379D0 (en) 1994-07-29 1994-07-29 Novel compounds
GB9415379.8 1994-07-29
US46829795A 1995-06-06 1995-06-06
US08/468,297 1995-06-06

Publications (1)

Publication Number Publication Date
WO1996004388A1 true WO1996004388A1 (fr) 1996-02-15

Family

ID=26305369

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/003036 Ceased WO1996004388A1 (fr) 1994-07-29 1995-07-28 Nouveaux composes

Country Status (13)

Country Link
EP (1) EP0770135A1 (fr)
JP (1) JPH10503371A (fr)
CN (1) CN1117155C (fr)
AU (1) AU3382595A (fr)
BR (1) BR9508469A (fr)
CA (1) CA2196200A1 (fr)
CZ (1) CZ25697A3 (fr)
HU (1) HUT76369A (fr)
MX (1) MX9700764A (fr)
NO (1) NO970374L (fr)
NZ (1) NZ292124A (fr)
PL (1) PL182665B1 (fr)
WO (1) WO1996004388A1 (fr)

Cited By (223)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998038212A3 (fr) * 1997-02-28 1999-01-14 Genetics Inst Polypeptides chimeriques contenant des domaines de chemokine
EP0812913A3 (fr) * 1996-06-12 1999-08-04 Smithkline Beecham Corporation Récepteur HR-1 appartenant la famille des récepteurs de cytokin
WO1999047538A1 (fr) 1998-03-19 1999-09-23 Human Genome Sciences, Inc. Analogue de chaine gamma commune de recepteur de cytokine
US5986059A (en) * 1996-06-14 1999-11-16 Bayer Corporation T-cell selective interleukin-4 agonists
US6028176A (en) * 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
US6287801B1 (en) * 1996-07-22 2001-09-11 Smithkline Beecham Corporation Nucleic acids encoding the G-protein coupled receptor HNFDS78
US6335426B1 (en) 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists
WO2002002641A1 (fr) 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte b
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
WO2001062272A3 (fr) * 2000-02-25 2002-03-28 Immunex Corp Recepteur soluble du facteur de necrose tumorale utilise dans le traitement de certaines affections medicales
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
WO2002070711A1 (fr) * 2001-03-03 2002-09-12 Glaxo Group Limited Vaccin
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
WO2002097033A2 (fr) 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Anticorps se liant de maniere immunospecifique a des recepteurs de trail
EP1173484A4 (fr) * 1999-04-28 2003-05-21 Genetics Inst Traitement de la fibrose par antagonisme de il-13 et de chaines receptrices de il-13
WO2003086458A1 (fr) 2002-04-12 2003-10-23 Medimmune, Inc. Anticorps anti-interleukine-9 recombinants
WO2004014292A2 (fr) 2002-05-10 2004-02-19 Purdue Research Foundation Anticorps monoclonaux agonistes de la epha2 et utilisations de ceux-ci
WO2004067026A1 (fr) * 2003-01-18 2004-08-12 Children's Hospital Medical Center Regulation de gene induit par allergene
US6838260B2 (en) 1997-12-08 2005-01-04 Emd Lexigen Research Center Corp. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
WO2005000892A2 (fr) 2003-06-12 2005-01-06 Eli Lilly And Company Proteines hybrides analogues de glp-1
WO2004110472A3 (fr) * 2003-06-12 2005-02-03 Lilly Co Eli Proteines de fusion
US6852508B1 (en) 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US6969517B2 (en) 2001-05-03 2005-11-29 Emd Lexigen Research Center Corp. Recombinant tumor specific antibody and use thereof
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
WO2005113606A3 (fr) * 2004-05-13 2006-05-04 Lilly Co Eli Proteines de fusion fgf-21
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2006068910A1 (fr) * 2004-12-22 2006-06-29 Eli Lilly And Company Preparations contenant une proteine hybride analogue du glp-1
EP1683865A2 (fr) 2001-02-02 2006-07-26 Eli Lilly & Company Protéines de mammifères en particulier CD200
US7091321B2 (en) 2000-02-11 2006-08-15 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of antibody-based fusion proteins
WO2006102095A2 (fr) 2005-03-18 2006-09-28 Medimmune, Inc. Rearrangement de l'infrastructure d'anticorps
US7141651B2 (en) 1999-08-09 2006-11-28 Emd Lexigen Research Center Corp. Multiple cytokine protein complexes
US7148321B2 (en) 2001-03-07 2006-12-12 Emd Lexigen Research Center Corp. Expression technology for proteins containing a hybrid isotype antibody moiety
WO2007002543A2 (fr) 2005-06-23 2007-01-04 Medimmune, Inc. Formulations d'anticorps possedant des profils d'agregation et de fragmentation optimises
US7169904B2 (en) 2002-12-17 2007-01-30 Emd Lexigen Research Center Corp. Immunocytokine sequences and uses thereof
US7186804B2 (en) 2001-12-04 2007-03-06 Emd Lexigen Research Center Corp. IL-2 fusion proteins with modulated selectivity
US7198789B2 (en) 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US7208577B2 (en) 1995-11-22 2007-04-24 Amgen, Inc. Methods of increasing lean tissue mass using OB protein compositions
US7211253B1 (en) 1999-11-12 2007-05-01 Merck Patentgesellschaft Mit Beschrankter Haftung Erythropoietin forms with improved properties
WO2007056352A2 (fr) 2005-11-07 2007-05-18 The Scripps Research Institute Compositions et procedes destines a controler la specificite de la signalisation du facteur tissulaire
CZ298203B6 (cs) * 1996-12-20 2007-07-18 Amgen Inc. Fúzní OB protein, sekvence nukleové kyseliny, vektor, hostitelská bunka, zpusob produkce proteinu ajeho pouzití pro výrobu léciva, farmaceutická kompozice
US7259002B2 (en) 2003-01-21 2007-08-21 Bristol-Myers Squibb Company Polynucleotide encoding a novel acyl coenzyme A, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof
WO2007147600A2 (fr) 2006-06-21 2007-12-27 Apogenix Gmbh Expression différentielle de la cytokine dans les cancers chez l'homme
US7323549B2 (en) 2003-12-30 2008-01-29 Emd Lexigen Research Center Corp. IL-7 fusion proteins
US7371381B2 (en) 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
WO2008105797A2 (fr) 2006-06-30 2008-09-04 Bristol-Myers Squibb Company Polynucléotides codant pour de nouveaux variants du pcsk9
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
WO2008136694A1 (fr) 2007-05-04 2008-11-13 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Domaines variables transgéniques d'anticorps de lapin et leurs utilisations
US7465447B2 (en) 2003-12-31 2008-12-16 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
US7482124B2 (en) 2005-07-08 2009-01-27 Bristol-Myers Squibb Company Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema
US7495085B2 (en) 2003-03-14 2009-02-24 Wyeth Antibodies against human or mouse IL-21 receptor
EP2027874A2 (fr) 2000-11-28 2009-02-25 Medimmune, Inc. Procédés d'administration/dosage d'anticorps anti-rsv pour la prophylaxie et le traitement
US7517526B2 (en) 2000-06-29 2009-04-14 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
US7544492B1 (en) 1994-08-17 2009-06-09 The Rockefeller University OB polypeptides, modified forms and derivatives
EP2080766A1 (fr) 2001-06-06 2009-07-22 Bristol-Myers Squibb Company Acides nucléiques et polypeptides apparentés à B7 utiles pour l'immunomodulation
WO2009092011A1 (fr) 2008-01-18 2009-07-23 Medimmune, Llc Anticorps obtenus par la cystéine pour conjugaison spécifique d'un site
US7585500B2 (en) 2004-11-17 2009-09-08 Amgen Inc. Fully human monoclonal antibodies to IL-13
US7589179B2 (en) 2004-12-09 2009-09-15 Merck Patent Gmbh IL-7 variants with reduced immunogenicity
EP2100619A1 (fr) 2003-02-20 2009-09-16 Seattle Genetics, Inc. Conjugués de médicaments d'anticorps anti-CD70 et leur utilisation pour le traitement du cancer et troubles immunitaires
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7645449B2 (en) 2003-02-07 2010-01-12 Giorgio Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
EP1805198A4 (fr) * 2004-09-22 2010-01-20 Aerovance Inc Muteines chimeres antagonistes vis-a-vis de l'interleukine-9 et de l'interleukine-4, et procedes d'utilisation
WO2010015608A1 (fr) 2008-08-05 2010-02-11 Novartis Ag Compositions et procédés pour des anticorps ciblant une protéine du complément c5
US7705123B2 (en) 1998-03-17 2010-04-27 Genetics Institute, Llc MU-1, member of the cytokine receptor family
EP1377826B1 (fr) * 2001-02-22 2010-06-09 The Research Foundation Of State University Of New York Recepteurs d'opiaces
EP2206516A1 (fr) 2002-06-14 2010-07-14 Medimmune, LLC Préparations d'anticorps anti-VRS liquides stabilisées
WO2010093993A2 (fr) 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Utilisation d'antagonistes de la protéine stimulant les lymphocytes b afin de favoriser la tolérance aux greffes
EP2228389A2 (fr) 2001-04-13 2010-09-15 Human Genome Sciences, Inc. Anticorps contre facteur de croissance endothéliale vasculaire 2
WO2010141329A1 (fr) 2009-06-01 2010-12-09 Medimmune, Llc Molecules a demi-vie prolongee et utilisations associees
EP2272566A2 (fr) 2003-08-18 2011-01-12 MedImmune, LLC Humanisation d'anticorps
WO2011020024A2 (fr) 2009-08-13 2011-02-17 The Johns Hopkins University Méthodes de modulation de la fonction immunitaire
WO2011018421A1 (fr) 2009-08-10 2011-02-17 Morphosys Ag Nouvelles stratégies de criblage pour l'identification de ligands
WO2011020079A1 (fr) 2009-08-13 2011-02-17 Calmune Corporation Anticorps contre le virus respiratoire syncytial (vrs) humain et procédés d'utilisation
EP2292663A2 (fr) 2006-08-28 2011-03-09 Kyowa Hakko Kirin Co., Ltd. Anticorps antagonistes monoclonaux humains specifiques á LIGHT humaine
WO2011035205A2 (fr) 2009-09-18 2011-03-24 Calmune Corporation Anticorps dirigés contre candida, leurs collectes et procédés d'utilisation
EP2301969A1 (fr) 2005-05-06 2011-03-30 ZymoGenetics, L.L.C. Anticorps monoclonaux IL-31 et procédés d'utilisation
EP2316487A1 (fr) 2003-04-11 2011-05-04 MedImmune, LLC Anticorps IL-9 recombinants et leurs utilisations
US7943342B2 (en) 2004-06-17 2011-05-17 Wyeth Llc Nucleic acids encoding IL-13 binding agents
US7973139B2 (en) 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
EP2341060A1 (fr) 2000-12-12 2011-07-06 MedImmune, LLC Molecules a demi-vies longues, compositions et utilisations de celles-ci
EP2357192A1 (fr) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Endokine alpha humain et methodes d'utilisation
EP2371389A2 (fr) 2002-08-14 2011-10-05 MacroGenics, Inc. Anticorps spécifiques au FcgammaRIIB et procédés d'utilisation associés
JP2011527567A (ja) * 2008-07-10 2011-11-04 アプロゲン インコーポレーテッド 動物細胞用組み換え発現ベクター
WO2011138391A1 (fr) 2010-05-06 2011-11-10 Novartis Ag Compositions et méthodes d'utilisation d'anticorps multivalents thérapeutiques de faible densité de la protéine apparentée à la lipoprotéine 6 (lrp6)
WO2011138392A1 (fr) 2010-05-06 2011-11-10 Novartis Ag Compositions et procédés d'utilisation d'anticorps thérapeutiques dirigés contre la protéine 6 liée à la lipoprotéine de basse densité (lrp6)
WO2012006596A2 (fr) 2010-07-09 2012-01-12 Calmune Corporation Anticorps anti-virus respiratoire syncytial (rsv) humain et procédés d'utilisation
EP2407548A1 (fr) 2006-10-16 2012-01-18 MedImmune, LLC Molécules ayant des demi-vies réduites, compositions et leurs utilisations
WO2012019061A2 (fr) 2010-08-05 2012-02-09 Stem Centrx, Inc. Nouveaux effecteurs et leurs procédés d'utilisation
WO2012022814A1 (fr) 2010-08-20 2012-02-23 Novartis Ag Anticorps pour le récepteur 3 du facteur de croissance épidermique (her3)
EP2422811A2 (fr) 2004-10-27 2012-02-29 MedImmune, LLC Modulation d'une spécificité d'anticorps par adaptation sur mesure de son affinité a une antigène apparente
WO2012027723A1 (fr) 2010-08-27 2012-03-01 Stem Centrx, Inc Modulateurs de la protéine de notum et leurs procédés d'utilisation
WO2012031273A2 (fr) 2010-09-03 2012-03-08 Stem Centrx, Inc. Nouveaux modulateurs et leurs procédés d'utilisation
EP2431054A2 (fr) 2000-06-15 2012-03-21 Human Genome Sciences, Inc. Facteur delta de nécrose de tumeur humaine et epsilon
WO2012058768A1 (fr) 2010-11-05 2012-05-10 Zymeworks Inc. Conception d'anticorps hétérodimérique stable ayant des mutations dans le domaine fc
WO2012069466A1 (fr) 2010-11-24 2012-05-31 Novartis Ag Molécules multi-spécifiques
WO2012078813A2 (fr) 2010-12-08 2012-06-14 Stem Centrx, Inc. Nouveaux modulateurs et procédés d'utilisation
EP2471817A2 (fr) 2007-12-07 2012-07-04 ZymoGenetics, Inc. Molécules d'anticorps humanisés spécifiques pour l'IL-31
US8221752B2 (en) 2004-06-09 2012-07-17 Wyeth Llc Antibodies against human interleukin-13 and uses therefor
WO2012112943A1 (fr) 2011-02-18 2012-08-23 Stem Centrx, Inc. Nouveaux modulateurs et méthodes d'utilisation associées
EP2505209A1 (fr) 2006-06-26 2012-10-03 MacroGenics, Inc. Anticorps spécifiques au FcgammaRIIB et procédés d'utilisation associés
EP2511299A1 (fr) 2005-04-19 2012-10-17 Seattle Genetics, Inc. Agents de liaison anti-CD70 humanisés et utilisations
WO2012172495A1 (fr) 2011-06-14 2012-12-20 Novartis Ag Compositions et procédés de ciblage du tem8 par des anticorps
EP2570432A1 (fr) 2002-06-14 2013-03-20 Medimmune, Inc. Formulations d'anticorps de virus syncytial anti-respiratoire (RSV) stabilisé
WO2013043071A1 (fr) 2011-09-23 2013-03-28 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Domaines de liaison à l'albumine modifiés et utilisations de ceux-ci pour améliorer la pharmacocinétique
US8420087B2 (en) 2004-01-05 2013-04-16 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
WO2013067055A1 (fr) 2011-11-01 2013-05-10 Bionomics, Inc. Procédés de blocage de la croissance des cellules souches cancéreuses
WO2013063702A1 (fr) 2011-11-04 2013-05-10 Zymeworks Inc. Structure d'anticorps hétérodimérique stable comprenant des mutations dans le domaine fc
WO2013067054A1 (fr) 2011-11-01 2013-05-10 Bionomics, Inc. Anticorps et procédés de traitement du cancer
WO2013067355A1 (fr) 2011-11-04 2013-05-10 Novartis Ag Constructions de protéine 6 liée à la lipoprotéine de basse densité (lrp6) prolongeant leur demi-vie
WO2013067060A1 (fr) 2011-11-01 2013-05-10 Bionomics, Inc. Anticorps anti-gpr49
WO2013067057A1 (fr) 2011-11-01 2013-05-10 Bionomics, Inc. Anticorps anti-gpr49
EP2594586A1 (fr) 2006-09-01 2013-05-22 ZymoGenetics, Inc. Anticorps monoclonaux IL-31 et procédés d'utilisation
WO2013081993A1 (fr) 2011-12-02 2013-06-06 Eli Lilly And Company Anticorps anti-glucagon et leurs utilisations
WO2013084147A2 (fr) 2011-12-05 2013-06-13 Novartis Ag Anticorps dirigés contre le récepteur 3 du facteur de croissance épidermique (her3)
WO2013084148A2 (fr) 2011-12-05 2013-06-13 Novartis Ag Anticorps pour le récepteur 3 du facteur de croissance épidermique (her3) dirigé contre le domaine ii de her3
WO2013093762A1 (fr) 2011-12-21 2013-06-27 Novartis Ag Compositions et procédés pour des anticorps ciblant le facteur p
WO2013093809A1 (fr) 2011-12-23 2013-06-27 Pfizer Inc. Régions constantes d'anticorps modifiés pour conjugaison spécifique à un site, et leurs procédés et utilisations
EP2609932A2 (fr) 2006-12-01 2013-07-03 Seattle Genetics, Inc. Agents se liant à des cibles variables et leurs utilisations
WO2013119960A2 (fr) 2012-02-08 2013-08-15 Stem Centrx, Inc. Nouveaux modulateurs et procédés d'utilisation
WO2013166594A1 (fr) 2012-05-10 2013-11-14 Zymeworks Inc. Constructions hétéromultimères de chaînes lourdes d'immunoglobulines comprenant des mutations dans le domaine fc
WO2014018625A1 (fr) 2012-07-25 2014-01-30 Kolltan Pharmaceuticals, Inc. Anticorps anti-kit et leurs utilisations
EP2703007A1 (fr) 2007-03-30 2014-03-05 MedImmune, LLC Anticorps ayant des profils de déamidation réduits
EP2711018A1 (fr) 2009-06-22 2014-03-26 MedImmune, LLC Régions Fc modifiées pour conjugaison spécifique d'un site
WO2014059028A1 (fr) 2012-10-09 2014-04-17 Igenica, Inc. Anticorps anti-c16orf54 et leurs méthodes d'utilisation
WO2014084859A1 (fr) 2012-11-30 2014-06-05 Novartis Ag Molécules et procédés pour la modulation d'activités de tmem16a
WO2014089111A1 (fr) 2012-12-05 2014-06-12 Novartis Ag Compositions et procédés pour des anticorps ciblant epo
WO2014099997A1 (fr) 2012-12-18 2014-06-26 Novartis Ag Compositions et procédés qui utilisent une étiquette peptidique qui se lie au hyaluronane
EP2769737A1 (fr) 2009-07-20 2014-08-27 Bristol-Myers Squibb Company Combinaison d'anticorps anti-ctla4 avec etoposide pour le traitement synergique de prolifération
WO2014159239A2 (fr) 2013-03-14 2014-10-02 Novartis Ag Anticorps dirigés contre notch 3
WO2014159562A1 (fr) 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Combinaison d'agoniste de dr5 et d'antagoniste anti-pd-1 et méthodes d'utilisation associées
US8852608B2 (en) 2009-02-02 2014-10-07 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US8907066B2 (en) 2009-04-22 2014-12-09 Merck Patent Gmbh Antibody fusion proteins with a modified FcRn binding site
WO2014197849A2 (fr) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Anticorps anti-c10orf54 et leurs utilisations
WO2014205300A2 (fr) 2013-06-21 2014-12-24 Novartis Ag Anticorps anti-récepteur1 de type lectine des ldl oxydées et procédés d'utilisation
WO2014205302A2 (fr) 2013-06-21 2014-12-24 Novartis Ag Anticorps du récepteur1 de ldl oxydé de type lectine et méthodes d'utilisation
US8937169B2 (en) 1996-01-11 2015-01-20 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US8986972B2 (en) 2012-02-24 2015-03-24 Stem Centrx, Inc. Nucleic acid encoding DLL3 antibodies
WO2015053871A2 (fr) 2013-08-26 2015-04-16 MabVax Therapeutics, Inc. Acides nucléiques codant des anticorps humains contre sialyl-lewisa
WO2015175375A1 (fr) 2014-05-13 2015-11-19 Short Jay M Protéines biologiques conditionnellement actives
WO2015187811A2 (fr) 2014-06-04 2015-12-10 MabVax Therapeutics, Inc. Anticorps monoclonal humain contre le ganglioside gd2
WO2015198217A2 (fr) 2013-02-08 2015-12-30 Novartis Ag Compositions et procédés pour anticorps à longue durée d'action ciblant l'il-17
WO2015198243A2 (fr) 2014-06-25 2015-12-30 Novartis Ag Compositions et procédés pour protéines à action longue
WO2015198240A2 (fr) 2014-06-25 2015-12-30 Novartis Ag Compositions et procédés permettant d'obtenir des protéines à action prolongée
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2016020882A2 (fr) 2014-08-07 2016-02-11 Novartis Ag Anticorps de type angiopoétine 4 (angptl4) et procédés d'utilisation
WO2016020880A2 (fr) 2014-08-07 2016-02-11 Novartis Ag Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants
WO2016057846A1 (fr) 2014-10-08 2016-04-14 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP3026123A1 (fr) 2006-04-27 2016-06-01 Klaritos, Inc. Procédé et trousses pour predire la thérapie par anticorps
WO2016098079A2 (fr) 2014-12-19 2016-06-23 Novartis Ag Compositions et méthodes associées à des anticorps ciblant bmp6
US9381205B2 (en) 2013-11-04 2016-07-05 Pfizer, Inc. Anti-EFNA4 antibody-drug conjugates
WO2016139482A1 (fr) 2015-03-03 2016-09-09 Kymab Limited Anticorps, utilisations et procédés associés
EP3073267A1 (fr) 2004-09-21 2016-09-28 Medimmune, Inc. Anticorps dirigés contre et procédés de production de vaccins pour virus respiratoire syncytial
EP3072525A1 (fr) 2007-05-14 2016-09-28 MedImmune, LLC Methodes de reduction de niveaux de basophiles
WO2016193872A2 (fr) 2015-06-05 2016-12-08 Novartis Ag Anticorps ciblant la protéine morphogénétique osseuse 9 (bmp9) et méthodes associées
WO2016207858A1 (fr) 2015-06-26 2016-12-29 Novartis Ag Anticorps de facteur xi et méthodes d'utilisation
US9546214B2 (en) 2014-04-04 2017-01-17 Bionomics, Inc. Humanized antibodies that bind LGR5
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
WO2017021893A1 (fr) 2015-08-03 2017-02-09 Novartis Ag Méthode de traitement des troubles associés au fgf21
WO2017042701A1 (fr) 2015-09-09 2017-03-16 Novartis Ag Anticorps de liaison à la lymphopoïétine stromale thymique (tslp) et méthodes d'utilisation des anticorps
US9676850B2 (en) 2012-02-24 2017-06-13 Abbvie Stemcentrx Llc Anti SEZ6 antibodies and methods of use
WO2017103895A1 (fr) 2015-12-18 2017-06-22 Novartis Ag Anticorps ciblant cd32b et leurs procédés d'utilisation associés
WO2017125897A1 (fr) 2016-01-21 2017-07-27 Novartis Ag Molécules multispécifiques ciblant cll-1
WO2017189724A1 (fr) 2016-04-27 2017-11-02 Novartis Ag Anticorps dirigés contre le facteur de différenciation de croissance 15 et leurs utilisations
WO2017203450A1 (fr) 2016-05-25 2017-11-30 Novartis Ag Agents d'inversion de liaison pour anticorps antifacteur xi/xia et utilisations correspondantes
WO2017216724A1 (fr) 2016-06-15 2017-12-21 Novartis Ag Méthodes de traitement de maladie à l'aide d'inhibiteurs de la protéine morphogénétique osseuse 6 (bmp6)
WO2018009507A1 (fr) 2016-07-06 2018-01-11 Bristol-Myers Squibb Company Combinaison d'un antagoniste tim -4 et procédés d'utilisation
WO2018083248A1 (fr) 2016-11-03 2018-05-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
US9968687B2 (en) 2013-02-22 2018-05-15 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates
US9993566B2 (en) 2013-08-28 2018-06-12 Abbvie Stemcentrx Llc SEZ6 modulators and methods of use
WO2018116255A1 (fr) 2016-12-23 2018-06-28 Novartis Ag Anticorps de facteur xi et méthodes d'utilisation
WO2018116267A2 (fr) 2016-12-23 2018-06-28 Novartis Ag Méthodes de traitement avec des anticorps anti-facteur xi/xia
US10035853B2 (en) 2013-08-28 2018-07-31 Abbvie Stemcentrx Llc Site-specific antibody conjugation methods and compositions
WO2018146594A1 (fr) 2017-02-08 2018-08-16 Novartis Ag Anticorps mimétiques du fgf21 et leurs utilisations
WO2018215935A1 (fr) 2017-05-24 2018-11-29 Novartis Ag Protéines à greffe de cytokine-anticorps et procédés d'utilisation contre des troubles liés à l'immunité
WO2018215938A1 (fr) 2017-05-24 2018-11-29 Novartis Ag Protéines greffées anticorps-cytokine et méthodes d'utilisation
WO2018215937A1 (fr) 2017-05-24 2018-11-29 Novartis Ag Protéines à greffe de cytokine-anticorps anti-interleukine-7 et procédés d'utilisation dans le traitement du cancer
WO2018215936A1 (fr) 2017-05-24 2018-11-29 Novartis Ag Protéines greffées d'anticorps-cytokine et procédés d'utilisation dans le traitement du cancer
US10144768B2 (en) 2015-12-04 2018-12-04 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation
WO2018229715A1 (fr) 2017-06-16 2018-12-20 Novartis Ag Compositions comprenant des anticorps anti-cd32b et procédés d'utilisation correspondants
WO2019073069A1 (fr) 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh Anticorps humains dirigés contre l'antigène thomsen-nouveau (tn)
WO2019081983A1 (fr) 2017-10-25 2019-05-02 Novartis Ag Anticorps ciblant cd32b et leurs procédés d'utilisation
US10308721B2 (en) 2014-02-21 2019-06-04 Abbvie Stemcentrx Llc Anti-DLL3 antibodies and drug conjugates for use in melanoma
US10428145B2 (en) 2015-09-29 2019-10-01 Celgene Corporation PD-1 binding proteins and methods of use thereof
WO2019197651A1 (fr) 2018-04-12 2019-10-17 Mediapharma S.R.L. Conjugué anticorps de lgals3bp-médicament et son utilisation pour le traitement du cancer
WO2019229658A1 (fr) 2018-05-30 2019-12-05 Novartis Ag Anticorps contre entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies
WO2019229701A2 (fr) 2018-06-01 2019-12-05 Novartis Ag Molécules de liaison dirigées contre bcma et leurs utilisations
US10513699B2 (en) 2014-09-03 2019-12-24 Bioatla, Llc Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
EP3590539A1 (fr) 2014-03-04 2020-01-08 Kymab Limited Anticorps, utilisations et procédés
WO2020016459A1 (fr) 2018-07-20 2020-01-23 Pierre Fabre Medicament Récepteur pour vista
US10548954B2 (en) 2010-07-09 2020-02-04 Bioverativ Therapeutics Inc. Factor IX polypeptides and methods of use thereof
WO2020068752A1 (fr) 2018-09-27 2020-04-02 Celgene Corporation PROTÉINES DE LIAISON SIRPα ET MÉTHODES D'UTILISATION DE CELLES-CI
WO2020079580A1 (fr) 2018-10-15 2020-04-23 Novartis Ag Anticorps stabilisant trem2
US10745487B2 (en) 2016-03-22 2020-08-18 Bionomics Limited Method of treating cancer by administering an anti-LGR5 monoclonal antibody
US10751414B2 (en) 2016-09-19 2020-08-25 Celgene Corporation Methods of treating psoriasis using PD-1 binding antibodies
US10766959B2 (en) 2014-12-11 2020-09-08 Pierre Fabre Medicament Anti-C10ORF54 antibodies and uses thereof
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
WO2020198731A2 (fr) 2019-03-28 2020-10-01 Danisco Us Inc Anticorps modifiés
EP3738981A1 (fr) 2014-01-24 2020-11-18 NGM Biopharmaceuticals, Inc. Anticorps liant beta-klotho 2 et leurs procédés d'utilisation
WO2020236792A1 (fr) 2019-05-21 2020-11-26 Novartis Ag Molécules de liaison à cd19 et utilisations de celles-ci
WO2020236797A1 (fr) 2019-05-21 2020-11-26 Novartis Ag Domaines de cd58 variants et leurs utilisations
EP3763740A1 (fr) 2011-01-26 2021-01-13 Celldex Therapeutics, Inc. Anticorps anti-kit et leurs utilisations
WO2021053559A1 (fr) 2019-09-18 2021-03-25 Novartis Ag Anticorps d'entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies
WO2021053560A1 (fr) 2019-09-18 2021-03-25 Novartis Ag Polythérapie avec des anticorps anti entpd2 et cd73
EP3842457A1 (fr) 2015-09-09 2021-06-30 Novartis AG Molécules de liaison de lymphopoïétine stromale thymique (tslp) et procédés d'utilisation des molécules
WO2021138264A1 (fr) 2019-12-30 2021-07-08 Seagen Inc. Méthodes de traitement du cancer à l'aide d'anticorps anti-cd70 non fucosylés
EP3888690A2 (fr) 2014-05-16 2021-10-06 MedImmune, LLC Molécules présentant une altération de liaison de récepteur fc néonatal ayant des propriétés thérapeutiques et diagnostiques améliorées
WO2021202473A2 (fr) 2020-03-30 2021-10-07 Danisco Us Inc Anticorps modifiés
WO2021220218A1 (fr) 2020-05-01 2021-11-04 Novartis Ag Variants d'immunoglobuline
WO2021220215A1 (fr) 2020-05-01 2021-11-04 Novartis Ag Immunoglobulines modifiées
US11319526B2 (en) 2008-05-02 2022-05-03 Seagen Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2022097060A1 (fr) 2020-11-06 2022-05-12 Novartis Ag Molécules de liaison à cd19 et utilisations associées
WO2022147463A2 (fr) 2020-12-31 2022-07-07 Alamar Biosciences, Inc. Molécules de liant ayant une affinité et/ou une spécificité élevées et leurs procédés de fabrication et d'utilisation
US11472876B2 (en) 2015-11-02 2022-10-18 Bioatla, Inc. Conditionally active polypeptides
WO2023278377A1 (fr) 2021-06-29 2023-01-05 Seagen Inc. Méthodes de traitement du cancer au moyen d'une combinaison d'un anticorps anti-cd70 non fucosylé et d'un antagoniste de cd47
WO2023131901A1 (fr) 2022-01-07 2023-07-13 Johnson & Johnson Enterprise Innovation Inc. Matériaux et procédés de protéines de liaison à il-1beta
WO2023209568A1 (fr) 2022-04-26 2023-11-02 Novartis Ag Anticorps multispécifiques ciblant il-13 et il-18
WO2024013727A1 (fr) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Matériau et procédés d'appariement amélioré par génie biologique de régions variables de liaison à l'antigène
WO2024015953A1 (fr) 2022-07-15 2024-01-18 Danisco Us Inc. Procédés de production d'anticorps monoclonaux
WO2024094755A1 (fr) * 2022-11-02 2024-05-10 Synerkine Pharma B.V. Immunocytokines modifiées, polypeptides de fusion et polypeptides il10
WO2024130158A1 (fr) 2022-12-16 2024-06-20 Modernatx, Inc. Nanoparticules lipidiques et polynucléotides codant l'interleukine-22 à demi-vie sérique étendue pour le traitement d'une maladie métabolique
US12134658B2 (en) 2020-08-03 2024-11-05 Janssen Biotech, Inc. Materials and methods for multidirectional biotransportation in virotherapeutics
WO2025104604A1 (fr) 2023-11-14 2025-05-22 Janssen Pharmaceuticals, Inc. Anticorps anti-virus respiratoire syncytial et leurs utilisations

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103265637B (zh) * 2013-06-04 2015-10-21 江苏众红生物工程创药研究院有限公司 一种重组猪白细胞介素4-Fc融合蛋白及其编码基因和表达方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (fr) * 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
EP0367166A1 (fr) * 1988-10-31 1990-05-09 Takeda Chemical Industries, Ltd. IL-2 modifiée et sa production
EP0464533A1 (fr) * 1990-06-28 1992-01-08 BEHRINGWERKE Aktiengesellschaft Protéines fusionnées avec des portions d'immunoglobulines, leurs production et utilisation
WO1993010235A1 (fr) * 1991-11-13 1993-05-27 Bayer Aktiengesellschaft Proteines mutantes de l'il-4 humaine mutante

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (fr) * 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
EP0307434A1 (fr) * 1987-03-18 1989-03-22 Medical Res Council Anticorps alteres.
EP0367166A1 (fr) * 1988-10-31 1990-05-09 Takeda Chemical Industries, Ltd. IL-2 modifiée et sa production
EP0464533A1 (fr) * 1990-06-28 1992-01-08 BEHRINGWERKE Aktiengesellschaft Protéines fusionnées avec des portions d'immunoglobulines, leurs production et utilisation
WO1993010235A1 (fr) * 1991-11-13 1993-05-27 Bayer Aktiengesellschaft Proteines mutantes de l'il-4 humaine mutante

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
S. ANGAL ET AL: "A singgle amino acid sustitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody", MOLECULAR IMMUNOLOGY, vol. 30, no. 1, pages 105 - 108 *
S.M. ZURAWSKI ET AL: "Receptors for Interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction", EMBO JOURNAL, vol. 12, no. 7, EYNSHAM, OXFORD GB, pages 2663 - 2670 *

Cited By (365)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US7544492B1 (en) 1994-08-17 2009-06-09 The Rockefeller University OB polypeptides, modified forms and derivatives
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7824675B2 (en) 1995-04-27 2010-11-02 Human Genome Sciences, Inc. Use of an antibody that binds human tumor necrosis factor receptor-like 2
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US7718400B2 (en) 1995-11-22 2010-05-18 Amylin Pharmaceuticals, Inc. Methods of increasing lean tissue mass using OB protein compositions
US7208577B2 (en) 1995-11-22 2007-04-24 Amgen, Inc. Methods of increasing lean tissue mass using OB protein compositions
US8080254B2 (en) 1995-11-22 2011-12-20 Amgen, Inc. OB fusion protein compositions and methods
US7112659B2 (en) 1995-11-22 2006-09-26 Amgen, Inc. OB fusion protein compositions and methods
US8937169B2 (en) 1996-01-11 2015-01-20 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
EP0812913A3 (fr) * 1996-06-12 1999-08-04 Smithkline Beecham Corporation Récepteur HR-1 appartenant la famille des récepteurs de cytokin
US6335426B1 (en) 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists
US5986059A (en) * 1996-06-14 1999-11-16 Bayer Corporation T-cell selective interleukin-4 agonists
US6433157B1 (en) 1996-06-14 2002-08-13 Bayer Corporation Polynucleotides encoding T-cell selective interleukin-4 agonists
US6028176A (en) * 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
US6313272B1 (en) 1996-07-19 2001-11-06 Bayer Corporation DNA encoding high affinity interleukin-4 muteins
US6287801B1 (en) * 1996-07-22 2001-09-11 Smithkline Beecham Corporation Nucleic acids encoding the G-protein coupled receptor HNFDS78
CZ298203B6 (cs) * 1996-12-20 2007-07-18 Amgen Inc. Fúzní OB protein, sekvence nukleové kyseliny, vektor, hostitelská bunka, zpusob produkce proteinu ajeho pouzití pro výrobu léciva, farmaceutická kompozice
US6100387A (en) * 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6852508B1 (en) 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
US7396911B2 (en) 1997-02-28 2008-07-08 Genetics Institute, Llc Chimeric polypeptides containing chemokine domains
WO1998038212A3 (fr) * 1997-02-28 1999-01-14 Genetics Inst Polypeptides chimeriques contenant des domaines de chemokine
US7282206B2 (en) 1997-04-30 2007-10-16 Wyeth Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US6838260B2 (en) 1997-12-08 2005-01-04 Emd Lexigen Research Center Corp. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US7226998B2 (en) 1997-12-08 2007-06-05 Emd Lexigen Research Center Corp. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US7576193B2 (en) 1997-12-08 2009-08-18 Merck Patent Gmbh Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US7994292B2 (en) 1998-03-17 2011-08-09 Genetics Institute, Llc MU-1, member of the cytokine receptor family
US7198789B2 (en) 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US7705123B2 (en) 1998-03-17 2010-04-27 Genetics Institute, Llc MU-1, member of the cytokine receptor family
EP1982990A1 (fr) 1998-03-19 2008-10-22 Human Genome Sciences, Inc. Récepteur de cytokine et chaîne de gamma commune similaire
WO1999047538A1 (fr) 1998-03-19 1999-09-23 Human Genome Sciences, Inc. Analogue de chaine gamma commune de recepteur de cytokine
EP2357192A1 (fr) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Endokine alpha humain et methodes d'utilisation
KR100862931B1 (ko) * 1999-04-28 2008-10-13 제네틱스 인스티튜트, 엘엘씨 Ｉｌ-13 및 ｉｌ-13 수용체 사슬의 길항작용에 의한섬유증의 치료 방법
EP1173484A4 (fr) * 1999-04-28 2003-05-21 Genetics Inst Traitement de la fibrose par antagonisme de il-13 et de chaines receptrices de il-13
EP2123674A1 (fr) * 1999-04-28 2009-11-25 Genetics Institute, LLC Traitement de la fibrose par l'antagonisme du récepteur IL-13 et/ou du IL-13
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7141651B2 (en) 1999-08-09 2006-11-28 Emd Lexigen Research Center Corp. Multiple cytokine protein complexes
US7582288B2 (en) 1999-08-09 2009-09-01 Merck Patent Gmbh Methods of targeting multiple cytokines
US7211253B1 (en) 1999-11-12 2007-05-01 Merck Patentgesellschaft Mit Beschrankter Haftung Erythropoietin forms with improved properties
US7507406B2 (en) 2000-02-11 2009-03-24 Emd Serono Research Center, Inc. Enhancing the circulating half-life of antibody-based fusion proteins
US7091321B2 (en) 2000-02-11 2006-08-15 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of antibody-based fusion proteins
WO2001062272A3 (fr) * 2000-02-25 2002-03-28 Immunex Corp Recepteur soluble du facteur de necrose tumorale utilise dans le traitement de certaines affections medicales
EP2431054A2 (fr) 2000-06-15 2012-03-21 Human Genome Sciences, Inc. Facteur delta de nécrose de tumeur humaine et epsilon
WO2002002641A1 (fr) 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte b
EP2275449A1 (fr) 2000-06-16 2011-01-19 Human Genome Sciences, Inc. Anticorps se liant de manière immunospécifique à un stimulateur de lymphocyte B
EP2281842A1 (fr) 2000-06-16 2011-02-09 Human Genome Sciences, Inc. Anticorps se liant de manière immunospécifique à un stimulateur de lymphocyte B
EP2281843A1 (fr) 2000-06-16 2011-02-09 Human Genome Sciences, Inc. Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte B
US7517526B2 (en) 2000-06-29 2009-04-14 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
EP2027874A2 (fr) 2000-11-28 2009-02-25 Medimmune, Inc. Procédés d'administration/dosage d'anticorps anti-rsv pour la prophylaxie et le traitement
EP2412384A1 (fr) 2000-11-28 2012-02-01 MedImmune, LLC Procédés d'administration/dosage d'anticorps anti-rsv pour la prophylaxie et le traitement
EP2338512A1 (fr) 2000-11-28 2011-06-29 MedImmune, LLC Procédés d'administration/dosage d'anticorps anti-rsv pour la prophylaxie et le traitement
EP2341060A1 (fr) 2000-12-12 2011-07-06 MedImmune, LLC Molecules a demi-vies longues, compositions et utilisations de celles-ci
EP2357187A1 (fr) 2000-12-12 2011-08-17 MedImmune, LLC Molécules à demi-vies longues, compositions et utilisations de celles-ci
EP3569610A2 (fr) 2000-12-12 2019-11-20 Medlmmune, LLC Molécules à demi-vies longues, compositions et utilisations associées
EP2354149A1 (fr) 2000-12-12 2011-08-10 MedImmune, LLC Molécules à demi-vies longues, compositions et utilisations de celles-ci
EP1683865A2 (fr) 2001-02-02 2006-07-26 Eli Lilly & Company Protéines de mammifères en particulier CD200
EP1377826B1 (fr) * 2001-02-22 2010-06-09 The Research Foundation Of State University Of New York Recepteurs d'opiaces
WO2002070711A1 (fr) * 2001-03-03 2002-09-12 Glaxo Group Limited Vaccin
JP2005502314A (ja) * 2001-03-03 2005-01-27 グラクソ　グループ　リミテッド ワクチン
US7148321B2 (en) 2001-03-07 2006-12-12 Emd Lexigen Research Center Corp. Expression technology for proteins containing a hybrid isotype antibody moiety
US8926973B2 (en) 2001-03-30 2015-01-06 Merck Patent Gmbh Reducing the immunogenicity of fusion proteins
US7601814B2 (en) 2001-03-30 2009-10-13 Merck Patent Gmbh Reducing the immunogenicity of fusion proteins
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
EP2228389A2 (fr) 2001-04-13 2010-09-15 Human Genome Sciences, Inc. Anticorps contre facteur de croissance endothéliale vasculaire 2
US6969517B2 (en) 2001-05-03 2005-11-29 Emd Lexigen Research Center Corp. Recombinant tumor specific antibody and use thereof
US7459538B2 (en) 2001-05-03 2008-12-02 Merck Patent Gmbh Recombinant tumor specific antibody and use thereof
WO2002097033A2 (fr) 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Anticorps se liant de maniere immunospecifique a des recepteurs de trail
EP2080766A1 (fr) 2001-06-06 2009-07-22 Bristol-Myers Squibb Company Acides nucléiques et polypeptides apparentés à B7 utiles pour l'immunomodulation
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
US7462350B2 (en) 2001-12-04 2008-12-09 Emd Serono Research Center, Inc. Cancer treatments including administering IL-2 fusion proteins with modulated selectivity
US7186804B2 (en) 2001-12-04 2007-03-06 Emd Lexigen Research Center Corp. IL-2 fusion proteins with modulated selectivity
WO2003086458A1 (fr) 2002-04-12 2003-10-23 Medimmune, Inc. Anticorps anti-interleukine-9 recombinants
EP2270049A2 (fr) 2002-04-12 2011-01-05 Medimmune, Inc. Anticorps anti-interleukine-9 recombinants
WO2004014292A2 (fr) 2002-05-10 2004-02-19 Purdue Research Foundation Anticorps monoclonaux agonistes de la epha2 et utilisations de ceux-ci
EP2327421A1 (fr) 2002-06-14 2011-06-01 MedImmune, LLC Préparations d'anticorps anti-VRS liquides stabilisées
EP2206516A1 (fr) 2002-06-14 2010-07-14 Medimmune, LLC Préparations d'anticorps anti-VRS liquides stabilisées
EP2570432A1 (fr) 2002-06-14 2013-03-20 Medimmune, Inc. Formulations d'anticorps de virus syncytial anti-respiratoire (RSV) stabilisé
EP2371389A2 (fr) 2002-08-14 2011-10-05 MacroGenics, Inc. Anticorps spécifiques au FcgammaRIIB et procédés d'utilisation associés
US7169904B2 (en) 2002-12-17 2007-01-30 Emd Lexigen Research Center Corp. Immunocytokine sequences and uses thereof
WO2004067026A1 (fr) * 2003-01-18 2004-08-12 Children's Hospital Medical Center Regulation de gene induit par allergene
US7259002B2 (en) 2003-01-21 2007-08-21 Bristol-Myers Squibb Company Polynucleotide encoding a novel acyl coenzyme A, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof
US7645449B2 (en) 2003-02-07 2010-01-12 Giorgio Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
EP2100619A1 (fr) 2003-02-20 2009-09-16 Seattle Genetics, Inc. Conjugués de médicaments d'anticorps anti-CD70 et leur utilisation pour le traitement du cancer et troubles immunitaires
EP2289559A1 (fr) 2003-02-20 2011-03-02 Seattle Genetics, Inc. Conjugués de médicaments d'anticorps anti-CD70 et leur utilisation pour le traitement du cancer et troubles immunitaires
US8143385B2 (en) 2003-03-14 2012-03-27 Wyeth Llc Nucleic acids coding for antibodies against human IL-21 receptor and uses therefor
US7495085B2 (en) 2003-03-14 2009-02-24 Wyeth Antibodies against human or mouse IL-21 receptor
EP2316487A1 (fr) 2003-04-11 2011-05-04 MedImmune, LLC Anticorps IL-9 recombinants et leurs utilisations
WO2005000892A2 (fr) 2003-06-12 2005-01-06 Eli Lilly And Company Proteines hybrides analogues de glp-1
CN101974090A (zh) * 2003-06-12 2011-02-16 伊莱利利公司 Glp-1类似物融合蛋白质
US8273854B2 (en) 2003-06-12 2012-09-25 Eli Lilly And Company GLP-1 analog fusion proteins
EA008831B1 (ru) * 2003-06-12 2007-08-31 Эли Лилли Энд Компани Слитые белки аналогов glp-1
WO2005000892A3 (fr) * 2003-06-12 2005-03-03 Lilly Co Eli Proteines hybrides analogues de glp-1
WO2004110472A3 (fr) * 2003-06-12 2005-02-03 Lilly Co Eli Proteines de fusion
EP2368909A1 (fr) * 2003-06-12 2011-09-28 Eli Lilly and Company Protéines à fusion analogue GLP-1
EP2272566A2 (fr) 2003-08-18 2011-01-12 MedImmune, LLC Humanisation d'anticorps
US7371381B2 (en) 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
US7323549B2 (en) 2003-12-30 2008-01-29 Emd Lexigen Research Center Corp. IL-7 fusion proteins
US7465447B2 (en) 2003-12-31 2008-12-16 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
US8420087B2 (en) 2004-01-05 2013-04-16 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
US7973139B2 (en) 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
US7576190B2 (en) 2004-05-13 2009-08-18 Eli Lilly And Company FGF-21 fusion proteins
WO2005113606A3 (fr) * 2004-05-13 2006-05-04 Lilly Co Eli Proteines de fusion fgf-21
US8221752B2 (en) 2004-06-09 2012-07-17 Wyeth Llc Antibodies against human interleukin-13 and uses therefor
US7943342B2 (en) 2004-06-17 2011-05-17 Wyeth Llc Nucleic acids encoding IL-13 binding agents
EP3073267A1 (fr) 2004-09-21 2016-09-28 Medimmune, Inc. Anticorps dirigés contre et procédés de production de vaccins pour virus respiratoire syncytial
EP1805198A4 (fr) * 2004-09-22 2010-01-20 Aerovance Inc Muteines chimeres antagonistes vis-a-vis de l'interleukine-9 et de l'interleukine-4, et procedes d'utilisation
EP2422811A2 (fr) 2004-10-27 2012-02-29 MedImmune, LLC Modulation d'une spécificité d'anticorps par adaptation sur mesure de son affinité a une antigène apparente
US7994302B2 (en) 2004-11-17 2011-08-09 Amgen Inc. Fully human monoclonal antibodies to IL-13
US7585500B2 (en) 2004-11-17 2009-09-08 Amgen Inc. Fully human monoclonal antibodies to IL-13
US7589179B2 (en) 2004-12-09 2009-09-15 Merck Patent Gmbh IL-7 variants with reduced immunogenicity
EP2168982A1 (fr) * 2004-12-22 2010-03-31 Eli Lilly & Company Formules de protéine fusion analogue GLP-1
WO2006068910A1 (fr) * 2004-12-22 2006-06-29 Eli Lilly And Company Preparations contenant une proteine hybride analogue du glp-1
EA011166B1 (ru) * 2004-12-22 2009-02-27 Эли Лилли Энд Компани Композиции слитых белков-аналогов glp-1
WO2006102095A2 (fr) 2005-03-18 2006-09-28 Medimmune, Inc. Rearrangement de l'infrastructure d'anticorps
EP2511299A1 (fr) 2005-04-19 2012-10-17 Seattle Genetics, Inc. Agents de liaison anti-CD70 humanisés et utilisations
EP2301969A1 (fr) 2005-05-06 2011-03-30 ZymoGenetics, L.L.C. Anticorps monoclonaux IL-31 et procédés d'utilisation
WO2007002543A2 (fr) 2005-06-23 2007-01-04 Medimmune, Inc. Formulations d'anticorps possedant des profils d'agregation et de fragmentation optimises
US7482124B2 (en) 2005-07-08 2009-01-27 Bristol-Myers Squibb Company Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema
WO2007056352A2 (fr) 2005-11-07 2007-05-18 The Scripps Research Institute Compositions et procedes destines a controler la specificite de la signalisation du facteur tissulaire
EP3026123A1 (fr) 2006-04-27 2016-06-01 Klaritos, Inc. Procédé et trousses pour predire la thérapie par anticorps
WO2007147600A2 (fr) 2006-06-21 2007-12-27 Apogenix Gmbh Expression différentielle de la cytokine dans les cancers chez l'homme
WO2007147600A3 (fr) * 2006-06-21 2008-04-10 Apogenix Gmbh Expression différentielle de la cytokine dans les cancers chez l'homme
EP2505209A1 (fr) 2006-06-26 2012-10-03 MacroGenics, Inc. Anticorps spécifiques au FcgammaRIIB et procédés d'utilisation associés
EP2671946A1 (fr) 2006-06-30 2013-12-11 Bristol-Myers Squibb Company Polynucléotides codant de nouveaux variants de PCSK9
WO2008105797A2 (fr) 2006-06-30 2008-09-04 Bristol-Myers Squibb Company Polynucléotides codant pour de nouveaux variants du pcsk9
EP2639301A2 (fr) 2006-06-30 2013-09-18 Bristol-Myers Squibb Company Polynucléotides codant de nouveaux variants de PCSK9
EP2484696A1 (fr) 2006-08-28 2012-08-08 Kyowa Hakko Kirin Co., Ltd. Anticorps monoclonaux humains anti-HLIGHT humain
EP2292663A2 (fr) 2006-08-28 2011-03-09 Kyowa Hakko Kirin Co., Ltd. Anticorps antagonistes monoclonaux humains specifiques á LIGHT humaine
EP2594586A1 (fr) 2006-09-01 2013-05-22 ZymoGenetics, Inc. Anticorps monoclonaux IL-31 et procédés d'utilisation
EP2759549A2 (fr) 2006-09-01 2014-07-30 ZymoGenetics, Inc. Anticorps monoclonaux IL-31 et procédés d'utilisation
EP2407548A1 (fr) 2006-10-16 2012-01-18 MedImmune, LLC Molécules ayant des demi-vies réduites, compositions et leurs utilisations
EP2609932A2 (fr) 2006-12-01 2013-07-03 Seattle Genetics, Inc. Agents se liant à des cibles variables et leurs utilisations
EP2703007A1 (fr) 2007-03-30 2014-03-05 MedImmune, LLC Anticorps ayant des profils de déamidation réduits
WO2008136694A1 (fr) 2007-05-04 2008-11-13 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Domaines variables transgéniques d'anticorps de lapin et leurs utilisations
EP3072525A1 (fr) 2007-05-14 2016-09-28 MedImmune, LLC Methodes de reduction de niveaux de basophiles
US11542327B2 (en) 2007-12-07 2023-01-03 Zymogenetics Inc. Methods of treating pruritic disease with IL-31 monoclonal antibodies
EP2471817A2 (fr) 2007-12-07 2012-07-04 ZymoGenetics, Inc. Molécules d'anticorps humanisés spécifiques pour l'IL-31
US9982044B2 (en) 2007-12-07 2018-05-29 Zymogenetics Inc. Method of treating pruritus with IL-31 monoclonal antibody formulations
US9005921B2 (en) 2007-12-07 2015-04-14 Zymogenetics, Inc. Polynucleotides encoding IL-31 monoclonal antibodies
US9416184B2 (en) 2007-12-07 2016-08-16 Zymogenetics, Inc. Method of treating pruritus with IL-31 monoclonal antibodies
US10640559B2 (en) 2007-12-07 2020-05-05 Zymogenetics, Inc. Nucleic acid molecules encoding humanized IL-31 monoclonal antibodies
US9738715B2 (en) 2007-12-07 2017-08-22 Zymogenetics Inc. IL-31 monoclonal antibody formulations
EP2796466A2 (fr) 2007-12-07 2014-10-29 ZymoGenetics, Inc. Molécules d'anticorps humanisés spécifiques pour l'IL-31
WO2009092011A1 (fr) 2008-01-18 2009-07-23 Medimmune, Llc Anticorps obtenus par la cystéine pour conjugaison spécifique d'un site
US11319526B2 (en) 2008-05-02 2022-05-03 Seagen Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
JP2011527567A (ja) * 2008-07-10 2011-11-04 アプロゲン インコーポレーテッド 動物細胞用組み換え発現ベクター
EP2837388A1 (fr) 2008-08-05 2015-02-18 Novartis AG Compositions et procédés pour anticorps ciblant une protéine C5 de complément
WO2010015608A1 (fr) 2008-08-05 2010-02-11 Novartis Ag Compositions et procédés pour des anticorps ciblant une protéine du complément c5
EP2815766A1 (fr) 2008-08-05 2014-12-24 Novartis AG Compositions et procédés pour des anticorps ciblant une protéine du complément C5
US8852608B2 (en) 2009-02-02 2014-10-07 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US9499590B2 (en) 2009-02-02 2016-11-22 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2010093993A2 (fr) 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Utilisation d'antagonistes de la protéine stimulant les lymphocytes b afin de favoriser la tolérance aux greffes
US8907066B2 (en) 2009-04-22 2014-12-09 Merck Patent Gmbh Antibody fusion proteins with a modified FcRn binding site
WO2010141329A1 (fr) 2009-06-01 2010-12-09 Medimmune, Llc Molecules a demi-vie prolongee et utilisations associees
EP2711018A1 (fr) 2009-06-22 2014-03-26 MedImmune, LLC Régions Fc modifiées pour conjugaison spécifique d'un site
EP2947098A1 (fr) 2009-07-20 2015-11-25 Bristol-Myers Squibb Company Combinaison d'anticorps anti-ctla4 avec gemcitabine pour le traitement synergique de prolifération
EP2769737A1 (fr) 2009-07-20 2014-08-27 Bristol-Myers Squibb Company Combinaison d'anticorps anti-ctla4 avec etoposide pour le traitement synergique de prolifération
EP3659596A1 (fr) 2009-07-20 2020-06-03 Bristol-Myers Squibb Company Combinaison d'anticorps anti-ctla4 avec paclitaxel pour le traitement synergique de prolifération
WO2011018421A1 (fr) 2009-08-10 2011-02-17 Morphosys Ag Nouvelles stratégies de criblage pour l'identification de ligands
WO2011020079A1 (fr) 2009-08-13 2011-02-17 Calmune Corporation Anticorps contre le virus respiratoire syncytial (vrs) humain et procédés d'utilisation
US8568719B2 (en) 2009-08-13 2013-10-29 Crucell Holland B.V. Antibodies against human respiratory syncytial virus (RSV) and methods of use
WO2011020024A2 (fr) 2009-08-13 2011-02-17 The Johns Hopkins University Méthodes de modulation de la fonction immunitaire
US9403900B2 (en) 2009-08-13 2016-08-02 Crucell Holland B.V. Anti-human respiratory syncytial virus (RSV) antibodies and methods of use
US9365638B2 (en) 2009-08-13 2016-06-14 Crucell Holland B. V. Antibodies against human respiratory syncytial virus (RSV) and methods of use
US9988437B2 (en) 2009-08-13 2018-06-05 Janssen Vaccines & Prevention B.V. Anti-human Respiratory Syncytial Virus (RSV) antibodies and methods of use
EP3381937A2 (fr) 2009-08-13 2018-10-03 The Johns Hopkins University Procédés de modulation de la fonction immune
WO2011035205A2 (fr) 2009-09-18 2011-03-24 Calmune Corporation Anticorps dirigés contre candida, leurs collectes et procédés d'utilisation
WO2011138392A1 (fr) 2010-05-06 2011-11-10 Novartis Ag Compositions et procédés d'utilisation d'anticorps thérapeutiques dirigés contre la protéine 6 liée à la lipoprotéine de basse densité (lrp6)
WO2011138391A1 (fr) 2010-05-06 2011-11-10 Novartis Ag Compositions et méthodes d'utilisation d'anticorps multivalents thérapeutiques de faible densité de la protéine apparentée à la lipoprotéine 6 (lrp6)
EP4234698A2 (fr) 2010-05-06 2023-08-30 Novartis AG Compositions et procédés d'utilisation d'anticorps thérapeutiques dirigés contre la protéine 6 liée à la lipoprotéine de basse densité (lrp6)
EP3345926A1 (fr) 2010-05-06 2018-07-11 Novartis AG Compositions et procédés d'utilisation d'anticorps thérapeutiques dirigés contre la protéine 6 liée à la lipoprotéine de basse densité (lrp6)
US10898554B1 (en) 2010-07-09 2021-01-26 Bioverativ Therapeutics Inc. Factor IX polypeptides and methods of use thereof
US10561714B2 (en) 2010-07-09 2020-02-18 Bioverativ Therapeutics Inc. Factor IX polypeptides and methods of use thereof
US10548954B2 (en) 2010-07-09 2020-02-04 Bioverativ Therapeutics Inc. Factor IX polypeptides and methods of use thereof
US10568943B2 (en) 2010-07-09 2020-02-25 Bioverativ Therapeutics Inc. Factor IX polypeptides and methods of use thereof
WO2012006596A2 (fr) 2010-07-09 2012-01-12 Calmune Corporation Anticorps anti-virus respiratoire syncytial (rsv) humain et procédés d'utilisation
US9139642B2 (en) 2010-07-09 2015-09-22 Crucell Holland B.V. Anti-human respiratory syncytial virus (RSV) antibodies and methods of use
WO2012019061A2 (fr) 2010-08-05 2012-02-09 Stem Centrx, Inc. Nouveaux effecteurs et leurs procédés d'utilisation
WO2012022814A1 (fr) 2010-08-20 2012-02-23 Novartis Ag Anticorps pour le récepteur 3 du facteur de croissance épidermique (her3)
WO2012027723A1 (fr) 2010-08-27 2012-03-01 Stem Centrx, Inc Modulateurs de la protéine de notum et leurs procédés d'utilisation
WO2012031273A2 (fr) 2010-09-03 2012-03-08 Stem Centrx, Inc. Nouveaux modulateurs et leurs procédés d'utilisation
WO2012058768A1 (fr) 2010-11-05 2012-05-10 Zymeworks Inc. Conception d'anticorps hétérodimérique stable ayant des mutations dans le domaine fc
WO2012069466A1 (fr) 2010-11-24 2012-05-31 Novartis Ag Molécules multi-spécifiques
US9765136B2 (en) 2010-12-08 2017-09-19 Abbvie Stemcentrx Llc Modulators and methods of use
US9969798B2 (en) 2010-12-08 2018-05-15 AbbVie Stemcentrx LLP Modulators and methods of use
US9320812B2 (en) 2010-12-08 2016-04-26 Stemcentrx, Inc. Modulators and methods of use
WO2012118547A1 (fr) 2010-12-08 2012-09-07 Stem Centrx, Inc. Nouveaux modulateurs et méthodes d'utilisation
WO2012078813A2 (fr) 2010-12-08 2012-06-14 Stem Centrx, Inc. Nouveaux modulateurs et procédés d'utilisation
EP3763740A1 (fr) 2011-01-26 2021-01-13 Celldex Therapeutics, Inc. Anticorps anti-kit et leurs utilisations
WO2012112943A1 (fr) 2011-02-18 2012-08-23 Stem Centrx, Inc. Nouveaux modulateurs et méthodes d'utilisation associées
EP3763388A1 (fr) 2011-02-18 2021-01-13 AbbVie Stemcentrx LLC Nouveaux modulateurs et procédés d'utilisation
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012172495A1 (fr) 2011-06-14 2012-12-20 Novartis Ag Compositions et procédés de ciblage du tem8 par des anticorps
WO2013043071A1 (fr) 2011-09-23 2013-03-28 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Domaines de liaison à l'albumine modifiés et utilisations de ceux-ci pour améliorer la pharmacocinétique
WO2013067055A1 (fr) 2011-11-01 2013-05-10 Bionomics, Inc. Procédés de blocage de la croissance des cellules souches cancéreuses
WO2013067060A1 (fr) 2011-11-01 2013-05-10 Bionomics, Inc. Anticorps anti-gpr49
US10196442B2 (en) 2011-11-01 2019-02-05 Bionomics Inc. Methods of inhibiting growth of a colon cancer tumor in a subject by administering monoclonal antibodies to G protein-coupled receptor 49 (GPR49)
WO2013067054A1 (fr) 2011-11-01 2013-05-10 Bionomics, Inc. Anticorps et procédés de traitement du cancer
WO2013067057A1 (fr) 2011-11-01 2013-05-10 Bionomics, Inc. Anticorps anti-gpr49
US10598653B2 (en) 2011-11-01 2020-03-24 Bionomics Inc. Methods of blocking cancer stem cell growth
US9221906B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Methods of inhibiting solid tumor growth by administering GPR49 antibodies
US9220774B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Methods of treating cancer by administering anti-GPR49 antibodies
US9221907B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Anti-GPR49 monoclonal antibodies
EP3252075A1 (fr) 2011-11-04 2017-12-06 Novartis AG Constructions de protéine 6 liée à la lipoprotéine de basse densité (lrp6) prolongeant leur demi-vie
WO2013067355A1 (fr) 2011-11-04 2013-05-10 Novartis Ag Constructions de protéine 6 liée à la lipoprotéine de basse densité (lrp6) prolongeant leur demi-vie
EP3290442A1 (fr) 2011-11-04 2018-03-07 Novartis AG Constructions de protéine 6 liée à la lipoprotéine de basse densité (lrp6) prolongeant leur demi-vie
WO2013063702A1 (fr) 2011-11-04 2013-05-10 Zymeworks Inc. Structure d'anticorps hétérodimérique stable comprenant des mutations dans le domaine fc
WO2013081993A1 (fr) 2011-12-02 2013-06-06 Eli Lilly And Company Anticorps anti-glucagon et leurs utilisations
EP3590538A1 (fr) 2011-12-05 2020-01-08 Novartis AG Anticorps dirigés contre le récepteur 3 du facteur de croissance épidermique (her3)
WO2013084148A2 (fr) 2011-12-05 2013-06-13 Novartis Ag Anticorps pour le récepteur 3 du facteur de croissance épidermique (her3) dirigé contre le domaine ii de her3
WO2013084147A2 (fr) 2011-12-05 2013-06-13 Novartis Ag Anticorps dirigés contre le récepteur 3 du facteur de croissance épidermique (her3)
EP3330288A1 (fr) 2011-12-21 2018-06-06 Novartis AG Compositions comprenant des anticorps ciblant le facteur p
WO2013093762A1 (fr) 2011-12-21 2013-06-27 Novartis Ag Compositions et procédés pour des anticorps ciblant le facteur p
WO2013093809A1 (fr) 2011-12-23 2013-06-27 Pfizer Inc. Régions constantes d'anticorps modifiés pour conjugaison spécifique à un site, et leurs procédés et utilisations
WO2013119960A2 (fr) 2012-02-08 2013-08-15 Stem Centrx, Inc. Nouveaux modulateurs et procédés d'utilisation
US9867887B1 (en) 2012-02-24 2018-01-16 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates
US11033634B2 (en) 2012-02-24 2021-06-15 Abbvie Stemcentrx Llc Light chain variable regions
US9358304B1 (en) 2012-02-24 2016-06-07 Stemcentrx, Inc. Methods of making DLL3 antibody drug conjugates
US9353182B2 (en) 2012-02-24 2016-05-31 Stemcentrx, Inc. Anti-DLL3 antibodies
US9931421B2 (en) 2012-02-24 2018-04-03 Abbvie Stemcentrx Llc Methods of delivering DLL3 antibody drug conjugates
US9089616B2 (en) 2012-02-24 2015-07-28 Stemcentrx, Inc. Anti-DLL3 antibody drug conjugates and methods of use
US9345784B1 (en) 2012-02-24 2016-05-24 Stemcentrx, Inc. Methods of delivering DLL3 antibody drug conjugates
US9334318B1 (en) 2012-02-24 2016-05-10 Stemcentrx, Inc. Multivalent DLL3 antibodies
US9878053B2 (en) 2012-02-24 2018-01-30 Abbvie Stemcentrx Llc Methods of delivering DLL3 antibody drug conjugates
US9937268B2 (en) 2012-02-24 2018-04-10 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates and methods of use
US8986972B2 (en) 2012-02-24 2015-03-24 Stem Centrx, Inc. Nucleic acid encoding DLL3 antibodies
US10533051B2 (en) 2012-02-24 2020-01-14 Abbvie Stemcentrx Llc Anti SEZ6 antibodies and methods of use
US9481727B2 (en) 2012-02-24 2016-11-01 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates
US9480757B2 (en) 2012-02-24 2016-11-01 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates
US9486537B2 (en) 2012-02-24 2016-11-08 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates
US9089617B2 (en) 2012-02-24 2015-07-28 Stemcentrx, Inc. Anti-DLL3 antibody drug conjugates
EP3095797A1 (fr) 2012-02-24 2016-11-23 Stemcentrx, Inc. Anticorps anti dll3 et procédés d'utilisation
US9861708B2 (en) 2012-02-24 2018-01-09 Abbvie Stemcentrx Llc Kits containing DLL3 antibody drug conjugates
US9855343B2 (en) 2012-02-24 2018-01-02 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates
US10137204B2 (en) 2012-02-24 2018-11-27 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates for treating cancer
US9090683B2 (en) 2012-02-24 2015-07-28 Stemcentrx, Inc. Methods of detection, diagnosis, and monitoring using anti-DLL3 antibodies
US9931420B2 (en) 2012-02-24 2018-04-03 Abbvie Stemcentrx Llc Methods of making DLL3 antibody drug conjugates
US9089615B2 (en) 2012-02-24 2015-07-28 Stemcentrx, Inc. Anti-DLL3 antibodies
US9676850B2 (en) 2012-02-24 2017-06-13 Abbvie Stemcentrx Llc Anti SEZ6 antibodies and methods of use
US9352051B1 (en) 2012-02-24 2016-05-31 Stemcentrx, Inc. Kits containing DLL3 antibody drug conjugates
US9173959B1 (en) 2012-02-24 2015-11-03 Stemcentrx, Inc. Anti-DLL3 antibody drug conjugates
US9155803B1 (en) 2012-02-24 2015-10-13 Stemcentrx, Inc. Anti-DLL3 antibody drug conjugates and methods of use
US9133271B1 (en) 2012-02-24 2015-09-15 Stemcentrx, Inc. Anti-DLL3 antibody drug conjugates and methods of use
US9764042B1 (en) 2012-02-24 2017-09-19 Abbvie Stemcentrx Llc Methods of making DLL3 antibody drug conjugates
US9770518B1 (en) 2012-02-24 2017-09-26 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates
US9775916B1 (en) 2012-02-24 2017-10-03 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates for treating cancer
US9107961B2 (en) 2012-02-24 2015-08-18 Stemcentrx, Inc. Anti-DLL3 antibody drug conjugates for treating cancer
WO2013166594A1 (fr) 2012-05-10 2013-11-14 Zymeworks Inc. Constructions hétéromultimères de chaînes lourdes d'immunoglobulines comprenant des mutations dans le domaine fc
EP3381943A1 (fr) 2012-07-25 2018-10-03 Celldex Therapeutics, Inc. Anticorps anti-kit et leurs utilisations
EP4063391A1 (fr) 2012-07-25 2022-09-28 Celldex Therapeutics, Inc. Anticorps anti-kit et leurs utilisations
WO2014018625A1 (fr) 2012-07-25 2014-01-30 Kolltan Pharmaceuticals, Inc. Anticorps anti-kit et leurs utilisations
WO2014059028A1 (fr) 2012-10-09 2014-04-17 Igenica, Inc. Anticorps anti-c16orf54 et leurs méthodes d'utilisation
WO2014084859A1 (fr) 2012-11-30 2014-06-05 Novartis Ag Molécules et procédés pour la modulation d'activités de tmem16a
WO2014089111A1 (fr) 2012-12-05 2014-06-12 Novartis Ag Compositions et procédés pour des anticorps ciblant epo
EP3851454A1 (fr) 2012-12-05 2021-07-21 Novartis AG Compositions et procédés pour des anticorps ciblant epo
WO2014099997A1 (fr) 2012-12-18 2014-06-26 Novartis Ag Compositions et procédés qui utilisent une étiquette peptidique qui se lie au hyaluronane
WO2015198217A2 (fr) 2013-02-08 2015-12-30 Novartis Ag Compositions et procédés pour anticorps à longue durée d'action ciblant l'il-17
US9968687B2 (en) 2013-02-22 2018-05-15 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates
US10478509B2 (en) 2013-02-22 2019-11-19 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates for treating cancer
EP3611189A1 (fr) 2013-03-14 2020-02-19 Novartis AG Anticorps dirigés contre notch 3
WO2014159562A1 (fr) 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Combinaison d'agoniste de dr5 et d'antagoniste anti-pd-1 et méthodes d'utilisation associées
EP3305812A1 (fr) 2013-03-14 2018-04-11 Bristol-Myers Squibb Company Combinaison d'agoniste dr5 et d'antagoniste anti-pd-1 et procédés d'utilisation
WO2014159239A2 (fr) 2013-03-14 2014-10-02 Novartis Ag Anticorps dirigés contre notch 3
US10414823B2 (en) 2013-06-06 2019-09-17 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
WO2014197849A2 (fr) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Anticorps anti-c10orf54 et leurs utilisations
US10100123B2 (en) 2013-06-06 2018-10-16 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
WO2014205302A2 (fr) 2013-06-21 2014-12-24 Novartis Ag Anticorps du récepteur1 de ldl oxydé de type lectine et méthodes d'utilisation
WO2014205300A2 (fr) 2013-06-21 2014-12-24 Novartis Ag Anticorps anti-récepteur1 de type lectine des ldl oxydées et procédés d'utilisation
WO2015053871A2 (fr) 2013-08-26 2015-04-16 MabVax Therapeutics, Inc. Acides nucléiques codant des anticorps humains contre sialyl-lewisa
EP3906945A2 (fr) 2013-08-26 2021-11-10 BioNTech Research and Development, Inc. Acides nucléiques codant des anticorps humains contre le sialyl-lewis a
US9475874B2 (en) 2013-08-26 2016-10-25 MabVax Therapeutics, Inc. Nucleic acids encoding human antibodies to sialyl-lewisa
US10035853B2 (en) 2013-08-28 2018-07-31 Abbvie Stemcentrx Llc Site-specific antibody conjugation methods and compositions
EP3338793A1 (fr) 2013-08-28 2018-06-27 AbbVie Stemcentrx LLC Nouveaux modulateurs sez6 et procédés d'utilisation
US9993566B2 (en) 2013-08-28 2018-06-12 Abbvie Stemcentrx Llc SEZ6 modulators and methods of use
US9381205B2 (en) 2013-11-04 2016-07-05 Pfizer, Inc. Anti-EFNA4 antibody-drug conjugates
US9872922B2 (en) 2013-11-04 2018-01-23 Pfizer Inc. Anti-EFNA4 antibody-drug conjugates
EP3738981A1 (fr) 2014-01-24 2020-11-18 NGM Biopharmaceuticals, Inc. Anticorps liant beta-klotho 2 et leurs procédés d'utilisation
US10308721B2 (en) 2014-02-21 2019-06-04 Abbvie Stemcentrx Llc Anti-DLL3 antibodies and drug conjugates for use in melanoma
EP3590539A1 (fr) 2014-03-04 2020-01-08 Kymab Limited Anticorps, utilisations et procédés
US9546214B2 (en) 2014-04-04 2017-01-17 Bionomics, Inc. Humanized antibodies that bind LGR5
US10358500B2 (en) 2014-04-04 2019-07-23 Bionomics Inc. Humanized antibodies that bind LGR5
WO2015175375A1 (fr) 2014-05-13 2015-11-19 Short Jay M Protéines biologiques conditionnellement actives
US10329556B2 (en) 2014-05-13 2019-06-25 Bioatla, Llc Conditionally active biological proteins
EP3888690A2 (fr) 2014-05-16 2021-10-06 MedImmune, LLC Molécules présentant une altération de liaison de récepteur fc néonatal ayant des propriétés thérapeutiques et diagnostiques améliorées
EP3868405A1 (fr) 2014-06-04 2021-08-25 BioNTech Research and Development, Inc. Anticorps monoclonaux humains pour ganglioside gd2
WO2015187811A2 (fr) 2014-06-04 2015-12-10 MabVax Therapeutics, Inc. Anticorps monoclonal humain contre le ganglioside gd2
US11760809B2 (en) 2014-06-04 2023-09-19 BioNTech SE Human monoclonal antibodies to ganglioside GD2
US10906988B2 (en) 2014-06-04 2021-02-02 Biontech Research And Development, Inc. Human monoclonal antibodies to ganglioside GD2
US9856324B2 (en) 2014-06-04 2018-01-02 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside GD2
WO2015198243A2 (fr) 2014-06-25 2015-12-30 Novartis Ag Compositions et procédés pour protéines à action longue
WO2015198240A2 (fr) 2014-06-25 2015-12-30 Novartis Ag Compositions et procédés permettant d'obtenir des protéines à action prolongée
WO2016020880A2 (fr) 2014-08-07 2016-02-11 Novartis Ag Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants
EP4122957A1 (fr) 2014-08-07 2023-01-25 Novartis AG Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants
WO2016020882A2 (fr) 2014-08-07 2016-02-11 Novartis Ag Anticorps de type angiopoétine 4 (angptl4) et procédés d'utilisation
US10513699B2 (en) 2014-09-03 2019-12-24 Bioatla, Llc Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
WO2016057841A1 (fr) 2014-10-08 2016-04-14 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et une thérapie anticancéreuse
WO2016057846A1 (fr) 2014-10-08 2016-04-14 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
US10766959B2 (en) 2014-12-11 2020-09-08 Pierre Fabre Medicament Anti-C10ORF54 antibodies and uses thereof
EP3800202A1 (fr) 2014-12-11 2021-04-07 Pierre Fabre Medicament Anticorps anti-c10orf54 et leurs utilisations
US11873339B2 (en) 2014-12-11 2024-01-16 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
WO2016098079A2 (fr) 2014-12-19 2016-06-23 Novartis Ag Compositions et méthodes associées à des anticorps ciblant bmp6
EP4137157A1 (fr) 2015-03-03 2023-02-22 Kymab Limited Anticorps, utilisations et procédés
WO2016139482A1 (fr) 2015-03-03 2016-09-09 Kymab Limited Anticorps, utilisations et procédés associés
WO2016193872A2 (fr) 2015-06-05 2016-12-08 Novartis Ag Anticorps ciblant la protéine morphogénétique osseuse 9 (bmp9) et méthodes associées
WO2016207858A1 (fr) 2015-06-26 2016-12-29 Novartis Ag Anticorps de facteur xi et méthodes d'utilisation
WO2017021893A1 (fr) 2015-08-03 2017-02-09 Novartis Ag Méthode de traitement des troubles associés au fgf21
EP3842457A1 (fr) 2015-09-09 2021-06-30 Novartis AG Molécules de liaison de lymphopoïétine stromale thymique (tslp) et procédés d'utilisation des molécules
WO2017042701A1 (fr) 2015-09-09 2017-03-16 Novartis Ag Anticorps de liaison à la lymphopoïétine stromale thymique (tslp) et méthodes d'utilisation des anticorps
US10428145B2 (en) 2015-09-29 2019-10-01 Celgene Corporation PD-1 binding proteins and methods of use thereof
US11472876B2 (en) 2015-11-02 2022-10-18 Bioatla, Inc. Conditionally active polypeptides
US10144768B2 (en) 2015-12-04 2018-12-04 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation
WO2017103895A1 (fr) 2015-12-18 2017-06-22 Novartis Ag Anticorps ciblant cd32b et leurs procédés d'utilisation associés
EP3851457A1 (fr) 2016-01-21 2021-07-21 Novartis AG Molécules multispécifiques ciblant cll-1
WO2017125897A1 (fr) 2016-01-21 2017-07-27 Novartis Ag Molécules multispécifiques ciblant cll-1
US10745487B2 (en) 2016-03-22 2020-08-18 Bionomics Limited Method of treating cancer by administering an anti-LGR5 monoclonal antibody
WO2017189724A1 (fr) 2016-04-27 2017-11-02 Novartis Ag Anticorps dirigés contre le facteur de différenciation de croissance 15 et leurs utilisations
EP4442270A2 (fr) 2016-05-25 2024-10-09 Novartis AG Agents de liaison inversibles pour anticorps anti-facteur xi/xia et leurs utilisations
WO2017203450A1 (fr) 2016-05-25 2017-11-30 Novartis Ag Agents d'inversion de liaison pour anticorps antifacteur xi/xia et utilisations correspondantes
WO2017216724A1 (fr) 2016-06-15 2017-12-21 Novartis Ag Méthodes de traitement de maladie à l'aide d'inhibiteurs de la protéine morphogénétique osseuse 6 (bmp6)
WO2018009507A1 (fr) 2016-07-06 2018-01-11 Bristol-Myers Squibb Company Combinaison d'un antagoniste tim -4 et procédés d'utilisation
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
US10751414B2 (en) 2016-09-19 2020-08-25 Celgene Corporation Methods of treating psoriasis using PD-1 binding antibodies
WO2018083248A1 (fr) 2016-11-03 2018-05-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
WO2018116255A1 (fr) 2016-12-23 2018-06-28 Novartis Ag Anticorps de facteur xi et méthodes d'utilisation
WO2018116267A2 (fr) 2016-12-23 2018-06-28 Novartis Ag Méthodes de traitement avec des anticorps anti-facteur xi/xia
WO2018146594A1 (fr) 2017-02-08 2018-08-16 Novartis Ag Anticorps mimétiques du fgf21 et leurs utilisations
WO2018215938A1 (fr) 2017-05-24 2018-11-29 Novartis Ag Protéines greffées anticorps-cytokine et méthodes d'utilisation
WO2018215935A1 (fr) 2017-05-24 2018-11-29 Novartis Ag Protéines à greffe de cytokine-anticorps et procédés d'utilisation contre des troubles liés à l'immunité
WO2018215937A1 (fr) 2017-05-24 2018-11-29 Novartis Ag Protéines à greffe de cytokine-anticorps anti-interleukine-7 et procédés d'utilisation dans le traitement du cancer
WO2018215936A1 (fr) 2017-05-24 2018-11-29 Novartis Ag Protéines greffées d'anticorps-cytokine et procédés d'utilisation dans le traitement du cancer
WO2018229715A1 (fr) 2017-06-16 2018-12-20 Novartis Ag Compositions comprenant des anticorps anti-cd32b et procédés d'utilisation correspondants
WO2019073069A1 (fr) 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh Anticorps humains dirigés contre l'antigène thomsen-nouveau (tn)
WO2019081983A1 (fr) 2017-10-25 2019-05-02 Novartis Ag Anticorps ciblant cd32b et leurs procédés d'utilisation
WO2019197651A1 (fr) 2018-04-12 2019-10-17 Mediapharma S.R.L. Conjugué anticorps de lgals3bp-médicament et son utilisation pour le traitement du cancer
WO2019229658A1 (fr) 2018-05-30 2019-12-05 Novartis Ag Anticorps contre entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies
WO2019229701A2 (fr) 2018-06-01 2019-12-05 Novartis Ag Molécules de liaison dirigées contre bcma et leurs utilisations
WO2020016459A1 (fr) 2018-07-20 2020-01-23 Pierre Fabre Medicament Récepteur pour vista
WO2020068752A1 (fr) 2018-09-27 2020-04-02 Celgene Corporation PROTÉINES DE LIAISON SIRPα ET MÉTHODES D'UTILISATION DE CELLES-CI
WO2020079580A1 (fr) 2018-10-15 2020-04-23 Novartis Ag Anticorps stabilisant trem2
WO2020198731A2 (fr) 2019-03-28 2020-10-01 Danisco Us Inc Anticorps modifiés
WO2020236797A1 (fr) 2019-05-21 2020-11-26 Novartis Ag Domaines de cd58 variants et leurs utilisations
WO2020236792A1 (fr) 2019-05-21 2020-11-26 Novartis Ag Molécules de liaison à cd19 et utilisations de celles-ci
WO2021053560A1 (fr) 2019-09-18 2021-03-25 Novartis Ag Polythérapie avec des anticorps anti entpd2 et cd73
WO2021053559A1 (fr) 2019-09-18 2021-03-25 Novartis Ag Anticorps d'entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies
US11820827B2 (en) 2019-12-30 2023-11-21 Seagen Inc. Methods of treating myelodysplastic syndrome and acute myeloid leukemia with nonfucosylated anti-CD70 antibodies
WO2021138264A1 (fr) 2019-12-30 2021-07-08 Seagen Inc. Méthodes de traitement du cancer à l'aide d'anticorps anti-cd70 non fucosylés
WO2021202473A2 (fr) 2020-03-30 2021-10-07 Danisco Us Inc Anticorps modifiés
WO2021220218A1 (fr) 2020-05-01 2021-11-04 Novartis Ag Variants d'immunoglobuline
WO2021220215A1 (fr) 2020-05-01 2021-11-04 Novartis Ag Immunoglobulines modifiées
US12134658B2 (en) 2020-08-03 2024-11-05 Janssen Biotech, Inc. Materials and methods for multidirectional biotransportation in virotherapeutics
WO2022097060A1 (fr) 2020-11-06 2022-05-12 Novartis Ag Molécules de liaison à cd19 et utilisations associées
WO2022147463A2 (fr) 2020-12-31 2022-07-07 Alamar Biosciences, Inc. Molécules de liant ayant une affinité et/ou une spécificité élevées et leurs procédés de fabrication et d'utilisation
WO2023278377A1 (fr) 2021-06-29 2023-01-05 Seagen Inc. Méthodes de traitement du cancer au moyen d'une combinaison d'un anticorps anti-cd70 non fucosylé et d'un antagoniste de cd47
WO2023131901A1 (fr) 2022-01-07 2023-07-13 Johnson & Johnson Enterprise Innovation Inc. Matériaux et procédés de protéines de liaison à il-1beta
WO2023209568A1 (fr) 2022-04-26 2023-11-02 Novartis Ag Anticorps multispécifiques ciblant il-13 et il-18
WO2024013727A1 (fr) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Matériau et procédés d'appariement amélioré par génie biologique de régions variables de liaison à l'antigène
WO2024015953A1 (fr) 2022-07-15 2024-01-18 Danisco Us Inc. Procédés de production d'anticorps monoclonaux
WO2024094755A1 (fr) * 2022-11-02 2024-05-10 Synerkine Pharma B.V. Immunocytokines modifiées, polypeptides de fusion et polypeptides il10
WO2024130158A1 (fr) 2022-12-16 2024-06-20 Modernatx, Inc. Nanoparticules lipidiques et polynucléotides codant l'interleukine-22 à demi-vie sérique étendue pour le traitement d'une maladie métabolique
WO2025104604A1 (fr) 2023-11-14 2025-05-22 Janssen Pharmaceuticals, Inc. Anticorps anti-virus respiratoire syncytial et leurs utilisations

Also Published As

Publication number Publication date
JPH10503371A (ja) 1998-03-31
EP0770135A1 (fr) 1997-05-02
AU3382595A (en) 1996-03-04
MX9700764A (es) 1997-05-31
CZ25697A3 (en) 1997-09-17
HUT76369A (en) 1997-08-28
NZ292124A (en) 1998-10-28
NO970374L (no) 1997-02-19
BR9508469A (pt) 1997-09-16
PL182665B1 (pl) 2002-02-28
NO970374D0 (no) 1997-01-28
PL318380A1 (en) 1997-06-09
CN1164872A (zh) 1997-11-12
CN1117155C (zh) 2003-08-06
CA2196200A1 (fr) 1996-02-15

Similar Documents

Publication Publication Date Title
US5783181A (en) Therapeutic uses of fusion proteins between mutant IL 4/IL13 antagonists and immunoglobulins
WO1996004388A1 (fr) Nouveaux composes
US20240327485A1 (en) Interleukin-2 muteins for the expansion of t-regulatory cells
US5457038A (en) Natural killer stimulatory factor
JP2644794B2 (ja) 新規な型のコロニー刺激因子―１
CA2372400C (fr) Expression et exportation de proteines interferon alpha en tant que proteines de fusion
JP2568394B2 (ja) 哺乳動物インターロイキン−４活性を示すポリペプチドをコードするヌクレオチド配列からなる核酸
US6433142B1 (en) Megakaryocyte stimulating factors
WO1997000319A2 (fr) Leptine chimirasee par fusion avec un domaine d'immunoglobuline et utilisation correspondante
US7122633B2 (en) Natural killer stimulatory factor
KR19990063653A (ko) 케모킨 억제제
AU606453B2 (en) Recombinant eukaryotic cells production interleukin-2, process and vectors for their preparation and process for the preparation of interleukin-2
WO1997023639A1 (fr) Procede de production de proteines fusionnees biologiquement actives
AU1196402A (en) Novel compounds
AU2140699A (en) Novel compounds
WO2000006596A2 (fr) HYBRIDES D'INTERFERON- alpha
US7235232B2 (en) Interferon alpha hybrids
WO2024253944A2 (fr) Protéine de fusion d'interleukine-15 et procédés d'utilisation
AU2023327477A1 (en) IL-15 MUTANT-FC/IL-15Rα SUBUNIT-FC HETERODIMER AND USE THEREOF

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 95195305.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 292124

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2196200

Country of ref document: CA

Ref document number: PV1997-256

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1019970700613

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1995930435

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1997 776492

Country of ref document: US

Date of ref document: 19970407

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1995930435

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019970700613

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV1997-256

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1995930435

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1019970700613

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV1997-256

Country of ref document: CZ